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Huntington’s disease (HD) is a hereditary neurodegenerative disorder that typically
manifests in midlife with motor, cognitive, and/or psychiatric symptoms. The disease
is caused by a CAG triplet expansion in exon 1 of the huntingtin gene and leads to
a severe neurodegeneration in the striatum and cortex. Classical electrophysiological
studies in genetic HD mouse models provided important insights into the disbalance of
excitatory, inhibitory and neuromodulatory inputs, as well as progressive disconnection
between the cortex and striatum. However, the involvement of local cortical and
striatal microcircuits still remains largely unexplored. Here we review the progress
in understanding HD-related impairments in the cortical and basal ganglia circuits,
and outline new opportunities that have opened with the development of modern
circuit analysis methods. In particular, in vivo imaging studies in mouse HD models
have demonstrated early structural and functional disturbances within the cortical
network, and optogenetic manipulations of striatal cell types have started uncovering
the causal roles of certain neuronal populations in disease pathogenesis. In addition,
the important contribution of astrocytes to HD-related circuit defects has recently been
recognized. In parallel, unbiased systems biology studies are providing insights into the
possible molecular underpinnings of these functional defects at the level of synaptic
signaling and neurotransmitter metabolism. With these approaches, we can now reach
a deeper understanding of circuit-based HD mechanisms, which will be crucial for the
development of effective and targeted therapeutic strategies.
Keywords: Huntington’s disease, cortex, basal ganglia, neural circuits, genetic mouse models, in vivo calcium
imaging, optogenetics
INTRODUCTION
Huntington’s disease (HD) is a devastating movement disorder that affects about 1 in 10,000
people. Among the heterogeneous group of neurodegenerative diseases, it takes a special role
based on its strictly genetic cause, i.e., an autosomal dominant mutation of the huntingtin (HTT)
gene on chromosome 4 (The Huntington’s Disease collaborative research group, 1993). The
repetition of a CAG codon above a number of 35 translates into an expanded polyglutamine
(polyQ) tract in the HTT protein, and causes a cascade of pathological events manifesting in
psychiatric, cognitive and motor symptoms. The disease usually starts in midlife, with age of onset
inversely correlating to CAG repeat number (Ross et al., 2014), and follows the course of three
consecutive stages. The initial stage is typically characterized by mood disorder, cognitive deficits,
and subtle motor impairments. In the second stage, excessive, abrupt, and involuntary movements
(chorea) become the dominant symptom, while motor skills such as gait, swallowing, and
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speech rapidly deteriorate. Cognitive capacities also continue
to decline, culminating in dementia. In the third stage, severe
weight loss and overall deterioration of health occurs and choreic
movements are replaced by bradykinesia and rigidity. Finally,
death becomes imminent 15 to 20 years after disease onset.
Pathologically, HD is characterized by neurodegeneration of
the basal ganglia, which is particularly severe in the striatum.
Prominent atrophy also occurs in the neocortex, the main input
region of the striatum, and in advanced disease stages other
brain regions become affected as well (Waldvogel et al., 2015).
Striatal atrophy mainly results from the loss of GABAergic
spiny projection neurons (SPNs), also known as medium spiny
neurons, while cortical neurodegeneration is most pronounced
in the motor and premotor areas and primarily affects cortical
pyramidal neurons (CPNs), also referred to as principal cells.
Importantly, changes in neuronal function occur long before
overt cell death is observed, suggesting that circuit alterations
underlie the early symptoms of the disease.
In this review we will outline the current understanding of
circuit mechanisms of HD based on investigations in available
genetic mouse models. As classical electrophysiological studies in
HD models have been extensively reviewed elsewhere (Raymond
et al., 2011; Galvan et al., 2012; Bunner and Rebec, 2016;
Plotkin and Goldberg, 2018), our main emphasis will be on the
most recent developments in the field enabled by technological
advances in circuit analysis, such as long-term in vivo
imaging, in vivo multi-channel electrophysiology, optogenetics,
and systems approaches for unbiased characterization of
transcriptomic and proteomic changes. With these tools at hand,
in the next few years it should be possible to not only accurately
describe the HD-related defects in cortical and basal ganglia
circuits, but also attempt to ameliorate them through cell type-
specific activity manipulations.
GENETIC MOUSE MODELS OF HD
A number of HD mouse models have been created over the years
since the discovery of the causal mutation in the HTT gene.
These models have been reviewed in detail elsewhere (Brooks
and Dunnett, 2013; Pouladi et al., 2013), and here we will only
highlight the ones that are most frequently used for the study
of HD-related circuit defects (Table 1). They can be divided into
truncated and full-length models, the latter including transgenic
and knock-in lines. Truncated models are all transgenic and
express an N-terminal fragment of HTT with a pathological
polyQ stretch. The R6 lines were the first HD mouse lines
to be generated and are among the best studied. The R6/2
mouse line contains ∼150 CAG repeats and shows an aggressive
phenotype with very early neurophysiological, histological, and
behavioral alterations and a lifespan of only ∼3–5 months
(Mangiarini et al., 1996).
Transgenic full-length models of HD express full-length
human mutant HTT (mHTT) and generally exhibit a slower
disease progression than truncated models. The yeast artificial
chromosome (YAC) transgenic strategy was used to generate
several mouse lines, named corresponding to their number of
CAG repeats: YAC18 (control), YAC46, YAC72, and YAC128
(Hodgson et al., 1999; Slow et al., 2003). The YAC128 mouse
exhibits striatal followed by cortical atrophy and mimics human
disease progression by displaying first a hyperkinetic and later
a hypokinetic phenotype (Slow et al., 2003). The bacterial
artificial chromosome (BAC) HD model carries 97 mixed CAA-
CAG repeats, shows reduced cortical and striatal volume and
progressive motor impairments (Gray et al., 2008).
Knock-in HD mouse models provide stronger construct
validity than transgenic models, as the CAG expansion is inserted
into the native murine Htt locus, thereby more closely resembling
the genetic context of HD patients. In these mice, brain atrophy
and motor defects slowly emerge in a protracted manner. Among
the knock-in models are the HD allelic series mice with various
CAG tract lengths, including CAG140 and the widely used zQ175
line (Menalled et al., 2002, 2003, 2012; Heikkinen et al., 2012).
Although no model perfectly reproduces all the aspects of the
human disease, the major findings on circuit phenotypes have
been quite consistent between various transgenic and knock-in
lines, strengthening the confidence that mouse models can deliver
important insights into pathogenic mechanisms of this disorder.
CIRCUITS AFFECTED IN HD
Two brain regions most vulnerable to HD are the basal ganglia
and the neocortex, which are extensively connected to each
other (Figure 1). The neocortex contains two major neuron
types: CPNs, which constitute ∼80% of all cortical neurons, and
interneurons, which account for the remaining 20% (Defelipe
et al., 2013; Huang, 2014). CPNs are excitatory glutamatergic
neurons with long-range projections connecting cortical areas
to each other or to subcortical structures. Interneurons are
inhibitory GABAergic cells with mostly local connections. Based
on the almost non-overlapping expression of molecular markers,
cortical interneurons are subdivided into three main populations
with distinct morphology, electrophysiological properties,
layer distribution and function: parvalbumin (PV)-positive,
somatostatin (SST)-positive and 5HT3a-receptor-positive cells
(Tremblay et al., 2016). PV cells are known to synapse onto
or close to the soma of CPNs and exert very fast and strong
inhibition onto their target cells (Pfeffer et al., 2013; Hu et al.,
2014), whereas SST cells form synapses on more distal dendrites
(Wang et al., 2004). 5HT3aR cells are very heterogeneous,
with a major subclass of this population expressing the marker
vasointestinal peptide (VIP). VIP cells preferentially synapse
onto SST interneurons (Pfeffer et al., 2013) (Figure 1).
The basal ganglia are a group of subcortical structures
including the striatum, globus pallidus (GP), ventral pallidum,
substantia nigra (SN), and subthalamic nucleus (STN). Within
the basal ganglia, striatum is the region receiving most of the
long-range input, including extensive glutamatergic innervation
from CPNs (Figure 1). Although these afferents come from
virtually all cortical areas, and are involved in many types
of sensory, cognitive and motor functions, here we will focus
on the motor circuitry relevant for HD, including motor
cortical areas and the dorsolateral striatum. Another source of
Frontiers in Neuroscience | www.frontiersin.org 2 February 2020 | Volume 14 | Article 82
fnins-14-00082 February 4, 2020 Time: 17:14 # 3
Blumenstock and Dudanova Circuit Mechanisms of Huntington’s Disease
TABLE 1 | Selected genetic HD mouse models*.
Model Type of genetic manipulation References
R6/2 Transgenic, human exon 1 fragment with ∼150 CAG repeats under human HTT promoter Mangiarini et al., 1996
YAC128 Transgenic, human full-length HTT with 128 CAG repeats Slow et al., 2003
BACHD Transgenic, human full-length HTT with 97 mixed CAA-CAG repeats Gray et al., 2008
CAG140 Knock-in, chimeric mouse/human exon 1 with 140 CAG repeats inserted into the murine Htt locus Menalled et al., 2003
zQ175 Knock-in derived from the CAG140 line, 188 CAG repeats Menalled et al., 2012
*This table is not intended to give a complete overview of existing mouse models of HD, but only contains the models widely used for circuits studies.
FIGURE 1 | Scheme of the cortical and striatal circuits involved in HD pathogenesis. Two insets on the top show the main elements of the local cortical and striatal
microcircuits. Roman numerals indicate cortical layers. For simplicity, only some of the cell types and connections between them are shown. CIN, cholinergic
interneuron; CPN, cortical pyramidal neuron; GPe, external segment of the globus pallidus; GPi, internal segment of the globus pallidus; PV, parvalbumin
interneuron; SNc, substantia nigra pars compacta; SNr, substantia nigra pars reticulata; SPN, spiny projection neuron; SST, somatostatin interneuron; STN,
subthalamic nucleus; VIP, vasointestinal peptide interneuron.
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glutamatergic afferents to the striatum is the thalamus. Apart
from these excitatory inputs, striatum also receives abundant
modulatory dopaminergic afferents from the substantia nigra
pars compacta (SNc).
GABAergic SPNs account for > 90% of striatal neurons and
are subdivided into two populations of approximately equal
size, giving rise to the two main striatal projections. The D1
dopamine receptor-expressing SPNs form the direct pathway,
and are therefore referred to as dSPNs. This pathway projects
directly to the output nuclei of the basal ganglia: the internal
part of the globus pallidus (GPi) and the substantia nigra
pars reticulata (SNr). The D2 dopamine receptor-positive SPNs
form the indirect pathway and are referred to as iSPNs. This
polysynaptic pathway connects to the output nuclei indirectly
via the external segment of the globus pallidus (GPe) and STN
(Figure 1) (Alexander and Crutcher, 1990). GPi and SNr consist
of GABAergic neurons that have pacemaker properties and
maintain tonic activity, continuously inhibiting their target cells
in the ventral anterior and ventral lateral nuclei of the thalamus
(Gerfen and Surmeier, 2011; Plotkin and Goldberg, 2018).
Thalamic nuclei in turn send glutamatergic projections to the
frontal cortex, forming the cortico-basal ganglia-thalamo-cortical
loop. The direct and indirect striatal projections have opposing
effects on the activity of the GABAergic cells in the GPi and SNr,
and thereby on the overall output of the basal ganglia. The direct
pathway inhibits the GPi/SNr activity and therefore has a net
excitatory effect on the thalamus and cortex, facilitating execution
of motor programs. Conversely, the indirect pathway disinhibits
the GABAergic neurons in the GPi/SNr, leading to reduced
activity of the thalamic and cortical neurons, and suppression
of undesired movements (Alexander and Crutcher, 1990; Gerfen
and Surmeier, 2011). It should be noted that this simple model of
two antagonistic striatal pathways has been refined in the recent
years by in vivo studies demonstrating simultaneous activation
of dSPN and iSPN cell clusters during motion initiation, as well
as similar correlation of their activity with locomotor behavior,
suggesting a more sophisticated functional arrangement of basal
ganglia circuits than previously thought (Cui et al., 2013; Barbera
et al., 2016; Klaus et al., 2017; Parker et al., 2018).
In addition to the direct and indirect pathways, a third,
hyperdirect pathway exists that bypasses the striatum and
connects the frontal cortex to the output nuclei via glutamatergic
neurons of the subthalamic nucleus (STN) (Figure 1). Like the
indirect projection, this pathway also has a net inhibitory action
on the thalamus and cortex. However, it conveys signals faster
than the indirect pathway, and is believed to be important for
precise timing of motor program initiation (Nambu et al., 2002).
Apart from SPNs, striatal microcircuits include multiple
groups of local interneurons: cholinergic interneurons (CINs)
and several types of GABAergic cells that can be distinguished by
the expression of molecular markers such as parvalbimun (PV),
neuropeptide Y (NPY), neuropeptide Y/somatostatin/nitric
oxide synthase (NPY/SST/NOS), calretinin (CR), and tyrosine
hydroxylase (TH). Overall, striatal interneurons receive similar
types of afferents as striatal SPNs (glutamatergic from cortex and
thalamus, and dopaminergic from SNc), and provide feedforward
inhibition onto SPNs, modulating their activity on different
time scales; however, each interneuron subtype has distinct
connectivity and physiology. Striatal PV interneurons are fast-
spiking cells (hence also referred to as FS interneurons) that
preferentially target the soma and proximal dendrites of SPNs,
providing fast and strong inhibitory inputs. All other GABAergic
interneurons fire at lower rates and form synapses on distal
SPN dendrites (Straub et al., 2016; Plotkin and Goldberg, 2018).
CINs in turn modulate the activity of GABAergic cells as well as
SPNs (Figure 1). There are also multiple connections between
different striatal interneuron subtypes that are just beginning to
be uncovered (Lee et al., 2017; Plotkin and Goldberg, 2018).
Although striatal interneurons provide the major source of
GABAergic inhibition to SPNs, other inhibitory inputs also
exist. Both dSPNs and iSPNs send collateral projections to
other SPNs belonging to both pathways (Gittis and Kreitzer,
2012). Another layer of inhibitory connectivity is added by
the reciprocal feedback projections between different nuclei of
the basal ganglia that complement the unidirectional cortico-
basal ganglia-thalamo-cortical loop described above (Plotkin and
Goldberg, 2018). The following sections explain the specific
defects that have been described in all these circuits during
disease progression in various HD mouse models. A brief
summary of these defects is given in Figures 2, 3.
Cortical Circuits
Cortical degeneration and dysfunction significantly contribute
to impairments in motor and executive functions and cognitive
abilities observed in HD. This is underlined by detailed
neuropathological studies in human post-mortem brains which
revealed a reduction in overall cortical area and cortical white
matter, associated with a marked cell loss. It is well-established
that CPNs are particularly vulnerable to HD, however region-
specific degeneration of interneurons also occurs (Kim et al.,
2014; Mehrabi et al., 2016). Interestingly, neuronal cell loss
in the cortex correlates with CAG repeat numbers (Halliday
et al., 1998), as well as with the clinical symptomatology,
such that patients with primarily motor symptoms show a
prominent reduction in cell numbers in the primary motor cortex
(Thu et al., 2010).
A growing body of evidence also highlights the fact that
structural and functional alterations in the cortex precede
neuronal loss by several years. The cortex of HD mutation
carriers shows progressive regional thinning in a topographically
predictable manner already up to 15 years before the onset
of motor symptoms (Rosas et al., 2005, 2008; Nopoulos et al.,
2010). On a functional level, one of the earliest events in HD
is increased cortical excitability and impaired GABA-mediated
cortical inhibition, as shown by transcranial magnetic stimulation
studies already in the presymptomatic phase of the disease
(Nardone et al., 2007; Schippling et al., 2009; Philpott et al., 2016;
Agarwal et al., 2019).
Similar findings were also reported and further extended
in HD mouse models, which exhibit multiple morphological
and electrophysiological abnormalities of cortical neurons.
Morphologically, dysmorphic dendrites and loss of dendritic
spines on CPNs was observed in R6/2 and knock-in mice
(Klapstein et al., 2001; Laforet et al., 2001). Chronic in vivo
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FIGURE 2 | Summary of cortical circuit alterations in rodent HD models. cond. HD, conditional HD mouse model; CPN, cortical pyramidal neuron; IN, interneuron;
PV, parvalbumin.
structural imaging furthermore demonstrated impaired spine
turnover and a progressive loss of persistent spines in
the somatosensory cortex (Murmu et al., 2013). Sensory
deprivation exacerbated the loss of persistent spines and impaired
stabilization of newly gained spines, suggesting that mHTT
promotes maladaptive synaptic plasticity (Murmu et al., 2015).
Electrophysiological studies in HD mouse models revealed
several changes in the basic membrane properties of CPNs,
such as an increase in input resistance, decrease in cell
membrane capacitance and depolarized resting membrane
potential (Cummings et al., 2006, 2009; Stern, 2011). These
alterations are known to affect synaptic plasticity and to make
cells more excitable and therefore prone to excitotoxic damage. In
addition to the elevated intrinsic excitability, there is an increase
in excitatory inputs to CPNs. Thus, behaviorally phenotypic R6/2
mice present higher frequency of spontaneous excitatory post-
synaptic potentials (EPSCs) and larger amplitudes of evoked
EPSCs in layer II/III CPNs. Likewise, increased excitatory drive
was also observed in the YAC128 and CAG140 models. Changes
in inhibitory post-synaptic currents (IPSCs) seem to be more
complex and variable between models: in R6/2 mice, IPSC
frequency is initially increased in presymptomatic animals, but
markedly declines at an advanced stage, while it is increased
at an advanced stage in two different full-length mouse models
(Cummings et al., 2009) (Figure 2).
In vivo electrophysiological recordings in R6/2 mice also
showed faster and less variable firing rates in the medial
prefrontal cortex. In addition, the firing pattern was temporally
altered, with mostly individual spikes instead of coordinated
bursts that typically occur in the WT cortex (Walker et al., 2008;
Miller et al., 2011) (Figure 2). Although it should be noted that
these parameters were not affected in knock-in HD mice, the
observations in R6/2 animals are consistent with the possibility
that the cortical activity is overall increased, but becomes “noisy”
and less structured, possibly leading to impaired information
processing in the cortex.
Recent advances in imaging techniques have allowed a more
detailed investigation of cortical network dysfunction in large
cell populations at single-cell resolution in a living animal. Using
in vivo calcium imaging in transgenic and knock-in HD mice,
we and others have demonstrated increased frequency of calcium
transients at the premanifest disease stage and at disease onset,
indicative of higher firing rates in CPNs as also suggested by
electrophysiological recordings (Arnoux et al., 2018; Burgold
et al., 2019; Donzis et al., 2019). In contrast, a decrease in calcium
transient frequency and amplitude was observed in advanced-
stage R6/2 and zQ175 knock-in mice (Donzis et al., 2019)
(Figure 2). Although further studies spanning presymptomatic
and symptomatic stages in the same mouse will be required
to reconcile these observations, taken together, the presently
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available findings suggest dynamic changes in the cortical
network during disease progression. An important advantage of
chronic imaging is the possibility to longitudinally follow activity
dynamics of single identified cells during disease course. This
enabled us to show that a large fraction of neurons in the primary
motor cortex of R6/2 mice become more active before the onset
of motor symptoms, and maintain higher activity as disease
progresses (Burgold et al., 2019).
In addition to the well-established perturbations of CPN
activity, there is significant evidence supporting the involvement
of cortical GABAergic interneurons in HD progression. Studies
in conditional HD mouse models pointed to the importance
of mHTT expression in cortical interneurons in addition to
CPNs and the role of cell-cell interactions between CPNs and
interneurons in the development of full-fledged cortical HD
pathology and behavioral defects (Gu et al., 2005). Moreover,
certain behavioral phenotypes were attributed specifically to
cortical interneuron dysfunction (Dougherty et al., 2014).
Electrophysiological recordings in HD mouse brain slices
demonstrated reduced inhibitory inputs onto CPNs, along with
reduced excitatory inputs onto PV interneurons and an altered
probability of GABA release (Gu et al., 2005; Spampanato et al.,
2008; Cummings et al., 2009). In agreement with these findings,
a reduction in perisomatic PV terminals around CPNs was
observed in both R6/2 mice and post-mortem HD patient tissue
(Burgold et al., 2019). Altogether, these studies suggest that
weakened inhibition might play a role in HD-related cortical
network dysfunction. It should be noted that apart from the few
studies on PV interneurons (Spampanato et al., 2008; Dougherty
et al., 2014), the contribution of other major cortical interneuron
types to HD is still largely unexplored.
The relevance of understanding interneuron function in HD
becomes even more apparent when we appreciate their role
in fine-tuning the activity of neuronal networks. GABAergic
neurons promote fast spike synchrony between excitatory
neurons and serve as pacemakers for generating neuronal
oscillations, temporally defined cortical rhythms produced by
coordinated activity of the network and important for cognitive
functions. Thus, autaptic self-connectivity among PV neurons
drives cortical oscillations in the gamma frequency range
(Connelly, 2014; Deleuze et al., 2019). SST interneuron in turn
are important for beta oscillations, and drive long-distance
coherence across cortical areas (Chen et al., 2017; Veit et al.,
2017). Interneurons are also believed to sculpt the functional
flexibility of cortical circuits, which is a key factor for shaping
behavior (Berke et al., 2004; Buzsáki et al., 2012; Cardin, 2019).
Studies in HD mouse models reach to some degree
contradictory conclusions concerning cortical network
synchrony assessed by correlations of simultaneously recorded
neuron pairs. In vivo electrophysiology demonstrated reductions
in spike synchrony in both transgenic and knock-in HD models
regardless of disease stage (Walker et al., 2008; Miller et al.,
2011; Stern, 2011), and implicated these deficits in behavioral
alterations (Walker et al., 2011). While reduced pairwise
synchrony was also observed in one in vivo calcium imaging
study (Donzis et al., 2019), other studies described an increase
in pairwise neuronal correlation as one of the earliest alterations
in both transgenic and knock-in HD mice (Arnoux et al., 2018;
Burgold et al., 2019). These initial insights call for further
investigation to clarify the spatial and temporal manner in which
network synchrony is affected in HD.
Corticostriatal Projection
Changes in the corticostriatal connections are among the
earliest events in disease progression, which occur before any
signs of cell death can be detected, and presumably underlie
the subtle motor deficits in premanifest HD (Reading et al.,
2004; Unschuld et al., 2012; Hintiryan et al., 2016; Reiner
and Deng, 2018). Disconnection from cortical afferents likely
plays a major role in the subsequent dysfunction of the
downstream striatal circuits. The breakdown of corticostriatal
communication in HD has been extensively studied, and for
detailed information the reader is referred to several excellent
reviews available on this topic (Miller and Bezprozvanny, 2010;
Raymond et al., 2011; Estrada-Sánchez and Rebec, 2013; Plotkin
and Surmeier, 2015; Bunner and Rebec, 2016; Rebec, 2018).
The conclusion that emerged from electrophysiological studies
in slices as well as in vivo in multiple HD mouse models
is that alterations in corticostriatal connections occur in two
phases, with increased glutamate release and SPN hyperexcitation
at the presymptomatic stage, followed by SPN silencing at
the symptomatic stage (Figure 3) (Klapstein et al., 2001;
Cepeda et al., 2003; Rebec et al., 2006; Joshi et al., 2009;
André et al., 2011b; Miller et al., 2011; Raymond et al., 2011;
Indersmitten et al., 2015; Rothe et al., 2015). The elevated
cortical activity observed early in disease causes an increased
excitatory drive onto striatal SPNs. Excess glutamate release from
the cortical synaptic terminals leads to sustained activation of
extrasynaptic NMDA receptors, triggering apoptotic mechanisms
in the SPNs (DiFiglia, 1990; Okamoto et al., 2009; Milnerwood
et al., 2010). Conversely, the decrease in SPN activity at
a later stage is due to progressive loss of cortical inputs.
Morphological investigations show a decrease in corticostriatal
synaptic terminals in symptomatic animals (Deng et al., 2013), as
well as progressive decline in spine densities on SPN dendrites
(Indersmitten et al., 2015).
In vivo electrophysiological studies in freely behaving mice
also analyzed local field potentials (LFPs), transient extracellular
signals generated by large populations of neurons. These
recordings uncovered altered synchrony between the cortical
and striatal networks in HD (Hong et al., 2012; Naze et al.,
2018). However, it is still unknown how cortical activity shapes
firing patterns in the striatum. A study combining wide-field
calcium imaging in the cortex with simultaneous multielectrode
recordings in the dorsal striatum elucidated some of the
principles of corticostriatal activity coupling during a behavioral
task (Peters et al., 2019). Such cellular resolution studies would
be invaluable to obtain a more comprehensive picture of
corticostriatal miscommunication in HD.
An important function of the corticostriatal afferents is
providing trophic support for SPNs, which are dependent on
brain-derived neurotrophic factor (BDNF) for survival. BDNF
is mainly produced in the cortex and delivered to the striatum
anterogradely via CPN axons (Altar et al., 1997). mHTT
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FIGURE 3 | Summary of striatal circuit alterations in rodent HD models. BDNF, brain-derived neurotrophic factor; CB1, cannabinoid receptor 1; DA, dopamine; eCB,
endocannabinoid; Glu, glutamate; HPLC, high-pressure liquid chromatography; IN, interneuron; ISH, in situ hybridization; LTD, long-term depression; NMDA-R,
N-methyl-D-aspartate receptor; PV, parvalbumin; qPCR, quantitative polymerase chain reaction; RT-PCR, reverse transcription polymerase chain reaction; SPN,
spiny projection neuron; SST, somatostatin; TrkB, tropomyosin receptor kinase B; WB, Western blot.
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decreases the levels of BDNF and its receptor tropomyosin-
related kinase B (TrkB) in human (Ferrer and Blanco, 2000;
Zuccato, 2001) and mouse brain (Spires, 2004; Zuccato et al.,
2005; Ginés et al., 2006). Moreover, impaired transport and
reduced release of BDNF has been observed in cortical neurons
of zQ175 mice (Yu et al., 2018). Genetic reduction of BDNF
in mice leads to striatal degeneration and expression profile
similar to human HD, arguing for a major contribution of
insufficient trophic support to striatal degeneration in HD
(Strand et al., 2007).
Abundant evidence of corticostriatal miscommunication and
impaired BDNF trophic support in HD obtained from studies in
brain slices and in vivo was also confirmed in a recent in vitro
approach using compartmentalized microfluidic chambers to
reconstitute corticostriatal connectivity in a dish (Virlogeux et al.,
2018). Consistent with previous findings, this study highlighted
the important contribution of cortical afferents to the functional
alterations observed in the post-synaptic striatal neurons.
It should be noted that in addition to the corticostriatal
projection, the glutamatergic thalamostriatal afferents are also
affected in various HD mouse models (Figure 3) (Kolodziejczyk
and Raymond, 2016; Parievsky et al., 2017) and might be
impaired even earlier than the cortical inputs (Deng et al., 2013).
However, our knowledge about their significance in disease
is still scarce.
Basal Ganglia Circuits
Among the striatal cells, iSPNs are the most vulnerable to mHTT
and are the first ones to degenerate (Reiner et al., 1988; Deng et al.,
2004). This results in disinhibition of the thalamic target neurons,
which is believed to underlie the hyperkinetic symptoms in HD.
At a later stage, when dSPNs also succumb to disease, dyskinesia
is replaced by akinesia and muscle stiffness (Albin et al., 1989;
Plotkin and Goldberg, 2018; Reiner and Deng, 2018). Long
before overt cell death occurs, SPNs start showing functional
abnormalities. Some of the well-established early alterations in
SPNs across various HD models are a depolarized membrane
potential, an increase in input resistance, and hyperexcitability
(Klapstein et al., 2001; Cepeda et al., 2003, 2013; Raymond et al.,
2011; Heikkinen et al., 2012; Indersmitten et al., 2015; Dvorzhak
et al., 2016; Parievsky et al., 2017). In addition, the two types of
SPNs exhibit differential changes in glutamatergic, GABAergic
inputs, and dopaminergic modulation, leading to an overall
increased activation of dSPNs in particular (André et al., 2011a,b;
Galvan et al., 2012; Deng et al., 2014). These functional changes
are believed to be crucial to the imbalance of the direct and
indirect pathway early in disease. It should be noted that recent
demonstration of overlapping dSPNs and iSPNs activity patterns
in vivo during motion (Cui et al., 2013; Barbera et al., 2016;
Klaus et al., 2017; Parker et al., 2018) raised the possibility that
disturbances occurring in HD likely go beyond a mere increase
or decrease in the firing rates of one or both SPN types.
In vivo recordings of spontaneous activity in the striatum
of freely behaving HD mice and rats revealed population-
level impairments in striatal activity with a reduction in
pairwise correlations and coincident bursts (Miller et al., 2008b,
2010). To obtain a more precise picture of these disturbances,
it will be necessary to monitor the activity of different
neuronal populations at a cellular resolution. However, while
striatal circuits in HD models have been extensively explored
in electrophysiological studies, their subcortical location has
presented a certain difficulty for imaging. The development of
head-mounted miniature microscopes that give optical access
to deep brain structures should accelerate progress in this area
(Werner et al., 2019). For example, calcium imaging in the
striatum of a pharmacological mouse model of Parkinson’s
disease revealed an imbalance of dSPNs and iSPN activity rates
along with more complex changes in the spatiotemporal activity
patterns and motion encoding that were specific to the iSPN
population (Parker et al., 2018). It will be exciting to see what
kind of changes can be uncovered by similar studies in freely
behaving HD mice.
While the main focus in HD research has been on interplay
between the direct and indirect pathways, more recent studies
have also revealed abnormalities in the STN function that might
contribute to motor impairments. In vivo extracellular recordings
combined with electrocorticography demonstrated increased
excitability of STN neurons in presymptomatic YAC128 animals,
and reduced cortico-subthalamic coherence in symptomatic
YAC128 and R6/2 mice. In addition, there was an overall decline
in spontaneous activity and altered firing pattern of STN neurons
(Callahan and Abercrombie, 2015a,b). These findings suggest that
early hyperexcitability and later disconnection from the cortex
is a general feature of cortico-basal ganglia projections in HD,
affecting corticostriatal as well as corticosubthalamic pathways.
Moreover, an ex vivo study in brain slices from two further
mouse models, zQ175 and BACHD, confirmed reduced activity
of STN neurons and attributed this reduction to an increased
activation of NMDA receptors, resulting oxidant stress, and
activation of KATP channels (Atherton et al., 2016). In addition
to these functional changes, age-dependent loss of STN neurons
was shown in human patients as well as HD mice (Lange et al.,
1976; Guo et al., 2012; Atherton et al., 2016).
Striatal inhibitory circuits also show multiple defects in
HD animals. Electrophysiological recordings demonstrated a
consistent increase in GABAergic transmission onto SPNs of
different mouse models, which in some cases occurred already
at the presymptomatic stage (Cepeda et al., 2004, 2010, 2013;
Centonze et al., 2005; Cummings et al., 2010; Indersmitten
et al., 2015; Hsu et al., 2018). This increase in striatal inhibition,
together with the loss of excitatory inputs, contributes to silencing
of SPNs as disease progresses. Interestingly, the alterations in
GABAergic inputs were distinct for the two types of SPNs,
with a stronger effect in iSPNs found in three different mouse
models at a symptomatic stage (André et al., 2011b; Galvan et al.,
2012; Cepeda et al., 2013). These differences likely exacerbate the
imbalance between the direct and indirect pathways.
Although the increase in inhibition onto SPNs is well-
established, the underlying cell types and circuit mechanisms
still remain to be deciphered. In contrast to SPNs, most local
interneurons are relatively spared in HD, with the exception
of PV interneurons, which are reduced in numbers in human
patients and R6/2 mice (Giampà et al., 2009; Reiner et al.,
2013; Reiner and Deng, 2018). A detailed analysis of PV cells
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in the zQ175 mouse model furthermore uncovered changes in
morphology, physiological properties, and connectivity (Holley
et al., 2019a). A recent study combining activity manipulation of
PV interneurons with simultaneous calcium imaging of PV cells
and SPNs in freely moving mice pointed to the function of PV
cells in facilitating execution of movement (Gritton et al., 2019);
it is therefore tempting to speculate that dysfunction and loss of
striatal PV interneurons may play a causal role in HD-related
akinesia, a hypothesis still to be tested in HD model animals.
Even though unchanged in numbers, other types of
interneurons are also likely to be functionally affected in
HD (Reiner and Deng, 2018). Recent studies started tackling
the contributions of different interneuron types using genetic
targeting and circuit manipulation tools (Cepeda et al., 2013;
Holley et al., 2015, 2019b; Tanimura et al., 2016). Thus,
optogenetic silencing of SST-positive interneurons [also referred
to as low-threshold spiking (LTS) interneurons] in brain slices
suggested a major contribution of this cell type to the increased
GABAergic inhibition in symptomatic zQ175 and R6/2 mice
(Holley et al., 2019b). In addition, the feedback inhibitory
connections between SPNs are also partially severed, and their
pattern is altered in HD mice, with a substantial number of
abnormal bidirectional connections between SPN pairs (Cepeda
et al., 2013). How this rewiring of SPNs contributes to their
dysfunction remains a subject for future research.
Taken together, accumulated evidence points to biphasic
alterations in SPNs as a result of multiple impairments in local
and extrastriatal inputs: after initial hyperexcitation at the early
stage, with disease progression the excitation/inhibition balance
tips toward increased inhibition (Figure 3) (Galvan et al., 2012;




Alterations in glutamate-driven flow of information from the
cortex to the striatum play a key role in the onset and progression
of HD. Yet, the corticostriatal system is tightly regulated by
dopamine (DA), a monoamine neuromodulator, which, together
with GABA signaling, provides crucial counterbalance and adds
flexibility to glutamatergic excitation of SPNs. In addition to
the disturbances of glutamate and GABA signaling described
above, many HD symptoms are therefore associated with altered
dopaminergic modulation.
The dopaminergic circuit anatomy as well as dopaminergic
signaling alterations in HD are described in detail in a number
of excellent articles (André et al., 2010; Gerfen and Surmeier,
2011; Tritsch and Sabatini, 2012; Chen et al., 2013; Gardoni
and Bellone, 2015; Rangel-Barajas and Rebec, 2016; Koch
and Raymond, 2019). Two major dopaminergic pathways that
innervate cortical and striatal areas and both show alterations
in HD are the nigrostriatal and mesocorticolimbic pathways.
The nigrostriatal pathway projects from the SNc to the
dorsal striatum and is implicated in cognitive function and
flexibility as well as in the control of movement (Bäckman and
Farde, 2001; Groenewegen, 2003; Sleezer and Hayden, 2016;
Andres and Darbin, 2018). In contrast, the mesocorticolimbic
pathway originates from dopaminergic neurons in the ventral
tegmental area (VTA) and ascends to the ventral striatum (or
nucleus accumbens) and large areas of the frontal cortex. The
mesocorticolimbic pathway plays a prominent role in motivation
and reward-driven behavior.
DA can modulate the function of both excitatory CPNs and
inhibitory SPNs on several levels, such as the probability
of neurotransmitter release, the post-synaptic receptor
sensitivity to the neurotransmitter (e.g., NMDA and AMPA
receptors), and post-synaptic integration and ensuing excitability
(Tritsch and Sabatini, 2012).
Intracellular DA signaling is mediated by a family of
G-protein coupled receptors (D1–D5 DA receptors), which
are grouped into two classes referred to as D1-like and D2-
like. Upon receptor activation, one of the main targets of the
recruited heterotrimeric G proteins is protein kinase A (PKA),
which is positively or negatively coupled to D1- and D2-like
receptors, respectively. As a consequence, the two classes of DA
receptors drive complimentary cellular effects. The two types
of SPNs show differential expression of DA receptors, with D1
receptors strongly enriched in dSPNs and D2 receptors in iSPNs
(Tritsch and Sabatini, 2012). D1- and D2-like receptors exert
opposite actions on presynaptic glutamate release and post-
synaptic glutamate receptor currents: D1-like receptor signaling
enhances glutamate release, depolarizes dSPNs, and increases
their activity, while D2-like receptor signaling inhibits glutamate
release, hyperpolarizes iSPNs, and leads to a decrease in their
activity (Gerfen and Surmeier, 2011; Tritsch and Sabatini,
2012). An optimal level of dopaminergic modulation and
balanced DA transmission between D1- and D2-like receptors
is required for efficient motor function and behavioral flexibility
(Chen et al., 2013).
In post-mortem HD brains, ∼40% dopaminergic neuron loss
can be observed in the SNc along with a significant decrease
in dopaminergic terminals in the striatum and loss of DA
transporter (DAT) (Oyanagi et al., 1989; Suzuki et al., 2001).
Transcriptional dysregulation of DA receptors in the striatum has
also been reported in HD patients and HD models, with both D1-
and D2-like receptors being reduced (Richfield et al., 1991; Weeks
et al., 1996; Bibb et al., 2000; Ariano et al., 2002; Petersén et al.,
2002; Pouladi et al., 2012).
During early disease progression, SPN loss is largely limited
to striosomes (Hedreen and Folstein, 1995). As these cells
project to the SNc, the death of these inhibitory neurons
is thought to initially hyperactivate the nigrostriatal pathway,
contributing to chorea and other clinical HD symptoms. First
evidence for altered DA transmission came from the observation
that pharmacologically increasing DA signaling in HD patients
worsens chorea, whereas reducing DA leads to akinesia (Bird,
1980; Spokes, 1980). A wealth of following studies showed
that progression of HD is accompanied by biphasic changes
in DA inputs that are intertwined with changes in glutamate
neurotransmission (Figure 3). The early symptomatic stage
characterized by chorea is reflected by excessive glutamate and
DA release, leading to a selective activation of the direct pathway
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and disinhibition of the thalamus. At a later stage, when chorea
is replaced by hypoactivity, a lack of sufficient glutamate and
DA signaling leads to the silencing of the direct pathway and
inhibition of the thalamus (Johnson et al., 2006; Joshi et al.,
2009; André et al., 2010, 2011b; Callahan and Abercrombie,
2011; Galvan et al., 2012; Rothe et al., 2015; Covey et al., 2016;
Koch and Raymond, 2019).
Additionally, D2-mediated DA signaling onto striatal CINs
generally reduces acetylcholine release and thereby dampens the
inhibition of dSPNs. In HD models, despite the survival of CINs
in the striatum, a dysregulation of acetylcholine release has been
reported (Reiner and Deng, 2018). By this mechanism, increased
levels of DA would exacerbate the imbalance toward activation
of the direct pathway, and promote the development of HD
symptoms (Smith-Dijak et al., 2019).
In cortical neurons, which receive both dopaminergic and
glutamatergic input, a disturbed signal-to-noise ratio and
reduced range over which DA and glutamate can be modulated
impairs both cognitive and motor functions (Kiyatkin and Rebec,
1999; Dallérac et al., 2011). An interesting theoretical framework
suggested that increased neural noise would therefore lead to
inflexibility of brain activity and as a consequence, behavioral
adaptations to environmental challenges would be impaired
(Hong and Rebec, 2012).
Importantly, HD is often accompanied by a range of
psychiatric symptoms, such as mood disorders, aggression,
compulsive behavior, psychotic episodes, apathy, and sexual
disorders (Roos, 2010; Tabrizi et al., 2013; Martinez-Horta et al.,
2016). A lack of interest in life activities and depression are the
most common mood symptoms of HD, appear early and continue
during HD progression, thereby becoming one of the most
disabling symptoms. This group of psychiatric symptoms has
been linked to dysfunctional activity of PFC (Epping and Paulsen,
2011; Grace, 2016), which receives prominent dopaminergic
input via the mesocorticolimbic pathway and plays a key role
in reward. Impaired D1 receptor-mediated DA transmission
was suggested to be involved in depression-like behaviors in
HD (Renoir et al., 2012), and loss of function of D2-SPNs in
the ventrolateral striatum causes motivational deficits without
affecting spontaneous behavior or reward preference (Tsutsui-
Kimura et al., 2017). Presymptomatic zQ175 mice further exhibit
suppressed motivation to work for reward and compromised
dopaminergic encoding of reward delivery in the nucleus
accumbens (Covey et al., 2016).
Modulation by Endocannabinoids
Endocannabinoids (eCBs), such as arachidonoylethanolamide
(AEA) and 2-arachidonylglycerol (2-AG), are small lipophilic
neuromodulators that are released from the post-synapse to
diffuse locally and act retrogradely on presynaptic CB1 receptors
where they inhibit neurotransmitter release. In the context of HD,
decreased CB1 expression can be detected early in disease in both
humans and animal models (Figure 3) (Denovan-Wright and
Robertson, 2000; Glass et al., 2000; Dowie et al., 2009; Van Laere
et al., 2010; Horne et al., 2013). Furthermore, changes in the levels
of endogenous endocannabinoids have been reported (Bisogno
et al., 2008), and CB1 knockout worsens motor performance
in HD mice (Blázquez et al., 2011; Mievis et al., 2011).
mHTT-dependent loss of CB1 furthermore disinhibits GABA
neurotransmission in SPNs, and is associated with progressive
decline of motor and cognitive function in HD models (Blázquez
et al., 2011; Chiarlone et al., 2014).
eCB signaling plays important roles in synaptic plasticity at
corticostriatal synapses. It modulates DA signaling to control
flexible goal-oriented and reward-driven behavior (Hilário et al.,
2007; Cui et al., 2015; Gremel et al., 2016; Augustin and
Lovinger, 2018), two processes that are compromised in HD
(Lawrence et al., 1996; Curtin et al., 2015). In the striatum,
eCBs drive long-term depression (LTD) at both excitatory
and inhibitory synapses (Huang et al., 2001). Striatal DA
signaling, in contrast, is not modulated directly by eCBs, but
is disinhibited indirectly via decreased GABAergic release at
CB1-expressing inhibitory afferents. A recent study showed that
accumbal eCB signaling inhibits CIN-driven DA release, whereas
CIN activation recruits production of 2-AG, thereby providing
negative feedback. Critically, 2-AG mobilization modifies DA-
dependent reward-driven behavior (Mateo et al., 2017), and it
has been shown that motivational deficits in HD mouse models
can be normalized by pharmacologic elevation of 2-AG signaling
at CB1 receptors (Covey et al., 2018). Additionally, attenuated
LTD at corticostriatal synapses could be restored by inhibiting
the degradation of 2-AG (Sepers et al., 2018), and viral delivery
of CB1 ameliorated some of the cellular dysfunction observed in
R6/2 mice (Chiarlone et al., 2014; Naydenov et al., 2014).
Activation of CB1 receptors seems to be neuroprotective,
possibly via inducing expression of BDNF (Blázquez et al., 2015).
It is furthermore suggested to play a role in the differential
vulnerability of iSPNs vs. dSPNs by protecting dSPNs in
particular (Ruiz-Calvo et al., 2018), although the mechanism
of this selectivity is not yet clear. Therefore, stabilization of
dopaminergic and endocannabinoid neuromodulatory systems
are attractive targets for novel drugs treating HD.
ROLE OF ASTROCYTES IN HD-RELATED
CIRCUIT DYSFUNCTION
In addition to the changes in various neuronal cell types described
above, astroglia has recently emerged as an important contributor
to neuronal dysfunction in HD (Khakh et al., 2017). Indeed,
mice selectively expressing mHTT in astrocytes exhibit age-
dependent motor deficits and shortened life span (Bradford et al.,
2009; Meunier et al., 2016). Astrocytic alterations have been so
far mostly studied in the striatum, where astrocytes seem to
play a crucial role in HD-related excitotoxicity via at least two
interrelated mechanisms.
First, astrocytes are equipped with glutamate transporters and
are responsible for the rapid clearance of extracellular glutamate
released at synapses (Ransom and Ransom, 2012). A well-
established HD phenotype in humans and mice is the loss of
the astrocytic glutamate transporter GLT1 (also called EAAT2)
(Arzberger et al., 1997; Liévens et al., 2001; Behrens, 2002; Shin
et al., 2005; Faideau et al., 2010; Cao et al., 2019), which is
probably due to transcriptional inhibition in the presence of
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mHTT (Bradford et al., 2009). Reduced expression of GLT-1
results in impaired glutamate uptake and increased extracellular
glutamate levels (Figure 3) (Liévens et al., 2001; Behrens, 2002;
Shin et al., 2005; Faideau et al., 2010; Estrada-Sánchez and
Rebec, 2012). Accordingly, increasing GLT-1 expression rescues
glutamate uptake and improves behavioral phenotypes in HD
mice (Miller et al., 2008a). It should be noted that this well-
established view was recently challenged by an in vivo imaging
study of glutamate dynamics, which showed normal glutamate
uptake in the striatum of HD mice (Parsons et al., 2016), a
controversy that remains to be resolved.
Second, astrocytes play an important role in extracellular
K+ buffering (Ransom and Ransom, 2012). This function is
also disturbed in HD, as expression of mHTT leads to a
downregulation of the Kir4.1 inwardly rectifying potassium
channel on the cell membrane of astrocytes, causing a shift in
the distribution of K+ ions across the membrane (Figure 3). The
resulting increase in K+ concentration in the extracellular space
is likely to be at least one of the underlying causes of depolarized
membrane potential and elevated excitability of SPNs (Tong et al.,
2014). In addition, it also depolarizes the membrane potential
of astrocytes and reduces the electrogenic uptake of glutamate
through the GLT-1 transporter, further impairing extracellular
glutamate clearance (Dvorzhak et al., 2016). A recent imaging
study with genetically encoded calcium and glutamate sensors
in brain slices of HD mice not only confirmed the prolonged
presence of extracellular glutamate after cortical stimulation,
but also demonstrated profound alterations of Ca2+ signaling
in astrocytes (Jiang et al., 2016). Interestingly, those defects
could be partially rescued by restoring Kir4.1 expression in
astrocytes, probably via improved GLT-1 expression and/or
function (Dvorzhak et al., 2016; Jiang et al., 2016).
INSIGHTS FROM SYSTEMS BIOLOGY
STUDIES
While electrophysiology and imaging have been useful to
describe the nature and time course of neural circuit dysfunction
in HD models, the molecular links between the HTT mutation
and neuronal miscommunication for a long time remained
elusive. Recently, powerful systems biology approaches have
provided important insights into these matters through large-
scale and unbiased screens at the transcriptomic and proteomic
levels. Next generation RNA-sequencing studies performed in
HD mouse models and human HD patient induced pluripotent
stem cell (iPSC)-derived or directly converted neural cultures
have all highlighted dysregulation of synaptic genes. In particular,
there was a downregulation of transcripts involved in the post-
synaptic scaffold, neurotransmitter signaling, Ca2+ signaling,
long-term synaptic plasticity, as well as reduced transcription
of neuronal activity-regulated genes (Langfelder et al., 2016;
HD iPSC Consortium, 2017; Veldman and Yang, 2018; Victor
et al., 2018). Importantly, these changes also hold true at the
proteomic level (Langfelder et al., 2016; Hosp et al., 2017;
Skotte et al., 2018). Quantitative mass spectrometry analysis in
R6/2 mice demonstrated a progressive decline of both excitatory
and inhibitory synaptic proteins (Burgold et al., 2019), in line
with morphological and functional defects described for both
types of synapses. Interestingly, synapse-related proteins are also
abundantly present in the mHTT interactome (Shirasaki et al.,
2012) and within insoluble mHTT inclusion bodies (Hosp et al.,
2017), suggesting that at least some of the synaptic defects
are directly caused by the mutant protein, rather than being a
secondary consequence of deteriorating neuronal health.
Systems biology studies furthermore deepened our
understanding of astrocytic dysfunction in HD mice, not
only by validating the reduction in glutamate transporters and
K+ channels, but also by unveiling mHTT-induced metabolic
disturbances in astrocytes (Langfelder et al., 2016; Skotte et al.,
2018; Diaz-Castro et al., 2019). Among the altered astrocytic
proteins were those involved in the glutamate-glutamine-GABA
neurotransmitter metabolic cycle. Isotope labeling experiments
in brain slices confirmed impaired astrocytic synthesis and/or
release of glutamine, which serves as a precursor for GABA
production in neurons and could play a role in the weakened
striatal inhibition (Skotte et al., 2018).
OPEN QUESTIONS AND FUTURE
DIRECTIONS
The impairments that occur in the principal neuron types in
the cortex (CPNs) and striatum (SPNs) have been thoroughly
characterized in the last two decades. Recent investigations
have also highlighted the contribution of astrocytes to circuit
dysfunction in HD. Despite these significant advances in
the knowledge about circuit mechanisms of HD, major
questions remain that will be particularly critical to address.
The microcircuit mechanisms involving cortical and striatal
interneurons are still largely unexplored. Moreover, it is not
clear how low-level changes in synaptic connectivity and
neuronal activity relate to higher-level changes such as network
synchronization and LFP oscillations across brain areas. It is
further not known whether and how such changes give rise to
behavioral symptoms. Progress in this area will be facilitated
by new techniques like multi-channel electrophysiology and
deep brain imaging that permit simultaneous recording of
large neuronal ensembles over prolonged periods of time.
Manipulation of neuronal activity in vivo using optogenetic or
chemogenetic approaches will be crucial to decipher the causal
role of distinct circuit elements in pathomechanisms of HD.
Moreover, viewing the described cell types as homogenous
populations is clearly an oversimplification. Single-cell RNA-
sequencing (scRNA-seq) studies are revealing an ever-greater
diversity of cortical neurons (Zeisel et al., 2015; Tasic et al., 2016,
2018) and challenging the classical subdivision of MSNs into two
discrete D1 and D2 classes (Gokce et al., 2016). How this complex
picture of cellular diversity is altered in diseases including HD
is completely unknown. Extension of the scRNA-seq approach
to HD models and human HD tissue will therefore be helpful
to shed more light on the involvement of different neuronal
and non-neuronal cell types and to tackle the enigmatic issue of
differential vulnerability to mHTT.
In vitro co-culture systems have been useful in delineating
the contribution of various afferents to SPN dysfunction
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(Kolodziejczyk and Raymond, 2016; Virlogeux et al., 2018).
The availability of HD neural cultures either derived from
iPSCs or directly converted from patients’ fibroblasts (HD
iPSC Consortium, 2017; Victor et al., 2018) now opens
the possibility of extending such in vitro approaches
to human neurons, thus providing a convenient and
physiologically relevant platform for drug testing. In
addition, brain organoids (Lancaster et al., 2013) and further
modifications of this technique that promote establishment
of functional neuronal connectivity (Giandomenico et al.,
2019) offer another promising way to bring in vitro
modeling of disease-related circuit impairments closer to the
in vivo setting.
At the molecular level, unbiased systems approaches
including transcriptomics and proteomics have delivered
important insights into the molecular underpinnings of neuronal
dysfunction in HD. However, extensive further work will
be required to link these molecular alterations to discrete
functional deficits.
In conclusion, the development of novel methodologies
allowing to monitor and manipulate neuronal activity in large
populations of neurons during natural behavior, and to detect
gene expression changes at a single-cell level, will enable a more
complete understanding of circuit mechanisms of HD, and might
open the doors for designing more refined therapies for this
devastating disorder.
AUTHOR CONTRIBUTIONS
Both authors wrote and edited the manuscript.
FUNDING
We acknowledge funding from the European Research Council
(grant FP7 GA ERC-2012-SyG_318987–ToPAG) and from the
Max Planck Society for the Advancement of Science.
ACKNOWLEDGMENTS
We thank Julia Kuhl for excellent assistance with the illustrations
and Petar Marinkovic´ for critically reading the manuscript.
REFERENCES
Agarwal, S., Koch, G., Hillis, A. E., Huynh, W., Ward, N. S., Vucic, S., et al. (2019).
Interrogating cortical function with transcranial magnetic stimulation: insights
from neurodegenerative disease and stroke. J. Neurol. Neurosurg. Psychiatry 90,
47–57. doi: 10.1136/jnnp-2017-317371
Albin, R. L., Young, A. B., and Penney, J. B. (1989). The functional anatomy of basal
ganglia disorders. Trends Neurosci. 12, 366–375. doi: 10.1016/0166-2236(89)
90074-x
Alexander, G. E., and Crutcher, M. D. (1990). Functional architecture of basal
ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 13,
266–271. doi: 10.1016/0166-2236(90)90107-l
Altar, C. A., Cai, N., Bliven, T., Juhasz, M., Conner, J. M., Acheson, A. L., et al.
(1997). Anterograde transport of brain-derived neurotrophic factor and its role
in the brain. Nature 389, 856–860. doi: 10.1038/39885
André, V. M., Cepeda, C., Fisher, Y. E., Huynh, M., Bardakjian, N., Singh, S., et al.
(2011a). Differential electrophysiological changes in striatal output neurons in
Huntington’s disease. J. Neurosci. 31, 1170–1182. doi: 10.1523/JNEUROSCI.
3539-10.2011
André, V. M., Cepeda, C., and Levine, M. S. (2010). Dopamine and glutamate
in Huntington’s disease: a balancing act: dopamine-glutamate balance in
Huntington’s disease. CNS Neurosci. Ther. 16, 163–178. doi: 10.1111/j.1755-
5949.2010.00134.x
André, V. M., Fisher, Y. E., and Levine, M. S. (2011b). Altered balance of activity
in the striatal direct and indirect pathways in mouse models of Huntington’s
disease. Front. Syst. Neurosci. 5:46. doi: 10.3389/fnsys.2011.00046
Andres, D. S., and Darbin, O. (2018). Complex dynamics in the Basal Ganglia:
health and disease beyond the motor system. J. Neuropsychiatry Clin. Neurosci.
30, 101–114. doi: 10.1176/appi.neuropsych.17020039
Ariano, M. A., Aronin, N., Difiglia, M., Tagle, D. A., Sibley, D. R., Leavitt, B. R., et al.
(2002). Striatal neurochemical changes in transgenic models of Huntington’s
disease. J. Neurosci. Res. 68, 716–729. doi: 10.1002/jnr.10272
Arnoux, I., Willam, M., Griesche, N., Krummeich, J., Watari, H., Offermann,
N., et al. (2018). Metformin reverses early cortical network dysfunction and
behavior changes in Huntington’s disease. eLife 7:e38744. doi: 10.7554/eLife.
38744
Arzberger, T., Krampfl, K., Leimgruber, S., and Weindl, A. (1997). Changes of
NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1)
mRNA expression in Huntington’s disease–an in situ hybridization study.
J. Neuropathol. Exp. Neurol. 56, 440–454. doi: 10.1097/00005072-199704000-
199704013
Atherton, J. F., McIver, E. L., Mullen, M. R., Wokosin, D. L., Surmeier, D. J., and
Bevan, M. D. (2016). Early dysfunction and progressive degeneration of the
subthalamic nucleus in mouse models of Huntington’s disease. eLife 5:e21616
doi: 10.7554/eLife.21616
Augustin, S. M., and Lovinger, D. M. (2018). Functional relevance of
endocannabinoid-dependent synaptic plasticity in the central nervous system.
ACS Chem. Neurosci. 9, 2146–2161. doi: 10.1021/acschemneuro.7b00508
Bäckman, L., and Farde, L. (2001). Dopamine and cognitive functioning: brain
imaging findings in Huntington’s disease and normal aging. Scand. J. Psychol.
42, 287–296. doi: 10.1111/1467-9450.00238
Barbera, G., Liang, B., Zhang, L., Gerfen, C. R., Culurciello, E., Chen, R.,
et al. (2016). Spatially compact neural clusters in the dorsal striatum encode
locomotion relevant information. Neuron 92, 202–213. doi: 10.1016/j.neuron.
2016.08.037
Behrens, P. F. (2002). Impaired glutamate transport and glutamate-glutamine
cycling: downstream effects of the Huntington mutation. Brain 125, 1908–1922.
doi: 10.1093/brain/awf180
Berke, J. D., Okatan, M., Skurski, J., and Eichenbaum, H. B. (2004). Oscillatory
entrainment of striatal neurons in freely moving rats. Neuron 43, 883–896.
doi: 10.1016/j.neuron.2004.08.035
Bibb, J. A., Yan, Z., Svenningsson, P., Snyder, G. L., Pieribone, V. A., Horiuchi,
A., et al. (2000). Severe deficiencies in dopamine signaling in presymptomatic
Huntington’s disease mice. Proc. Natl. Acad. Sci. U.S.A. 97, 6809–6814. doi:
10.1073/pnas.120166397
Bird, E. D. (1980). Chemical pathology of Huntington’s disease. Annu. Rev.
Pharmacol. Toxicol. 20, 533–551. doi: 10.1146/annurev.pa.20.040180.002533
Bisogno, T., Martire, A., Petrosino, S., Popoli, P., and Di Marzo, V. (2008).
Symptom-related changes of endocannabinoid and palmitoylethanolamide
levels in brain areas of R6/2 mice, a transgenic model of Huntington’s disease.
Neurochem. Int. 52, 307–313. doi: 10.1016/j.neuint.2007.06.031
Blázquez, C., Chiarlone, A., Bellocchio, L., Resel, E., Pruunsild, P., García-Rincón,
D., et al. (2015). The CB1 cannabinoid receptor signals striatal neuroprotection
via a PI3K/Akt/mTORC1/BDNF pathway. Cell Death Differ. 22, 1618–1629.
doi: 10.1038/cdd.2015.11
Blázquez, C., Chiarlone, A., Sagredo, O., Aguado, T., Pazos, M. R., Resel, E., et al.
(2011). Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor
in Huntington’s disease. Brain 134, 119–136. doi: 10.1093/brain/awq278
Frontiers in Neuroscience | www.frontiersin.org 12 February 2020 | Volume 14 | Article 82
fnins-14-00082 February 4, 2020 Time: 17:14 # 13
Blumenstock and Dudanova Circuit Mechanisms of Huntington’s Disease
Bradford, J., Shin, J.-Y., Roberts, M., Wang, C.-E., Li, X.-J., and Li, S.
(2009). Expression of mutant huntingtin in mouse brain astrocytes causes
age-dependent neurological symptoms. Proc. Natl. Acad. Sci. U.S.A. 106,
22480–22485. doi: 10.1073/pnas.0911503106
Brooks, S. P., and Dunnett, S. B. (2013). “Mouse models of Huntington’s disease,”
in Behavioral Neurobiology of Huntington’s Disease and Parkinson’s Disease,
eds H. H. P. Nguyen, and M. A. Cenci, (Berlin: Springer Berlin Heidelberg),
101–133. doi: 10.1007/7854_2013_256
Bunner, K. D., and Rebec, G. V. (2016). Corticostriatal dysfunction in Huntington’s
disease: the basics. Front. Hum. Neurosci. 10:317. doi: 10.3389/fnhum.2016.
00317
Burgold, J., Schulz-Trieglaff, E. K., Voelkl, K., Gutiérrez-Ángel, S., Bader, J. M.,
Hosp, F., et al. (2019). Cortical circuit alterations precede motor impairments in
Huntington’s disease mice. Sci. Rep. 9:6634. doi: 10.1038/s41598-019-43024-w
Buzsáki, G., Anastassiou, C. A., and Koch, C. (2012). The origin of extracellular
fields and currents — EEG. ECoG, LFP and spikes. Nat. Rev. Neurosci. 13,
407–420. doi: 10.1038/nrn3241
Callahan, J. W., and Abercrombie, E. D. (2011). In vivo dopamine eﬄux is
decreased in striatum of both fragment (R6/2) and full-length (YAC128)
transgenic mouse models of Huntington’s disease. Front. Syst. Neurosci. 5:61.
doi: 10.3389/fnsys.2011.00061
Callahan, J. W., and Abercrombie, E. D. (2015a). Age-dependent alterations in the
cortical entrainment of subthalamic nucleus neurons in the YAC128 mouse
model of Huntington’s disease. Neurobiol. Dis. 78, 88–99. doi: 10.1016/j.nbd.
2015.03.006
Callahan, J. W., and Abercrombie, E. D. (2015b). Relationship between subthalamic
nucleus neuronal activity and electrocorticogram is altered in the R6/2 mouse
model of Huntington’s disease. J. Physiol. 593, 3727–3738. doi: 10.1113/
JP270268
Cao, J. K., Viray, K., Zweifel, L., and Stella, N. (2019). Sex-dependent impaired
locomotion and motor coordination in the HdhQ200/200 mouse model of
Huntington’s disease. Neurobiol. Dis. 132:104607. doi: 10.1016/j.nbd.2019.
104607
Cardin, J. A. (2019). Functional flexibility in cortical circuits. Curr. Opin. Neurobiol.
58, 175–180. doi: 10.1016/j.conb.2019.09.008
Centonze, D., Rossi, S., Prosperetti, C., Tscherter, A., Bernardi, G., Maccarrone, M.,
et al. (2005). Abnormal sensitivity to cannabinoid receptor stimulation might
contribute to altered gamma-aminobutyric acid transmission in the striatum of
R6/2 Huntington’s disease mice. Biol. Psychiatry 57, 1583–1589. doi: 10.1016/j.
biopsych.2005.03.008
Cepeda, C., Cummings, D. M., André, V. M., Holley, S. M., and Levine,
M. S. (2010). Genetic mouse models of Huntington’s disease: focus
on electrophysiological mechanisms. ASN Neuro 2:e00033. doi: 10.1042/
AN20090058
Cepeda, C., Galvan, L., Holley, S. M., Rao, S. P., Andre, V. M., Botelho, E. P.,
et al. (2013). Multiple sources of striatal inhibition are differentially affected in
Huntington’s disease mouse models. J. Neurosci. 33, 7393–7406. doi: 10.1523/
JNEUROSCI.2137-12.2013
Cepeda, C., Hurst, R. S., Calvert, C. R., Hernández-Echeagaray, E., Nguyen,
O. K., Jocoy, E., et al. (2003). Transient and progressive electrophysiological
alterations in the corticostriatal pathway in a mouse model of Huntington’s
disease. J. Neurosci. 23, 961–969. doi: 10.1523/JNEUROSCI.23-03-00961.2003
Cepeda, C., Starling, A. J., Wu, N., Nguyen, O. K., Uzgil, B., Soda, T., et al. (2004).
Increased GABAergic function in mouse models of Huntington’s disease:
reversal by BDNF. J. Neurosci. Res. 78, 855–867. doi: 10.1002/jnr.20344
Chen, G., Zhang, Y., Li, X., Zhao, X., Ye, Q., Lin, Y., et al. (2017). Distinct inhibitory
circuits orchestrate cortical beta and gamma band oscillations. Neuron 96:1403-
1418.e6. doi: 10.1016/j.neuron.2017.11.033
Chen, J. Y., Wang, E. A., Cepeda, C., and Levine, M. S. (2013). Dopamine imbalance
in Huntington’s disease: a mechanism for the lack of behavioral flexibility. Front.
Neurosci. 7:114. doi: 10.3389/fnins.2013.00114
Chiarlone, A., Bellocchio, L., Blazquez, C., Resel, E., Soria-Gomez, E., Cannich,
A., et al. (2014). A restricted population of CB1 cannabinoid receptors with
neuroprotective activity. Proc. Natl. Acad. Sci. U.S.A. 111, 8257–8262. doi: 10.
1073/pnas.1400988111
Connelly, W. M. (2014). Autaptic connections and synaptic depression constrain
and promote gamma oscillations. PLoS One 9:e89995. doi: 10.1371/journal.
pone.0089995
Covey, D. P., Dantrassy, H. M., Yohn, S. E., Castro, A., Conn, P. J., Mateo, Y.,
et al. (2018). Inhibition of endocannabinoid degradation rectifies motivational
and dopaminergic deficits in the Q175 mouse model of Huntington’s disease.
Neuropsychopharmacology 43, 2056–2063. doi: 10.1038/s41386-018-0107-108
Covey, D. P., Dantrassy, H. M., Zlebnik, N. E., Gildish, I., and Cheer,
J. F. (2016). Compromised dopaminergic encoding of reward accompanying
suppressed willingness to overcome high effort costs is a prominent prodromal
characteristic of the Q175 mouse model of Huntington’s disease. J. Neurosci.
Off. J. Soc. Neurosci. 36, 4993–5002. doi: 10.1523/JNEUROSCI.0135-16.2016
Cui, G., Jun, S. B., Jin, X., Pham, M. D., Vogel, S. S., Lovinger, D. M., et al.
(2013). Concurrent activation of striatal direct and indirect pathways
during action initiation. Nature 494, 238–242. doi: 10.1038/nature
11846
Cui, Y., Paillé, V., Xu, H., Genet, S., Delord, B., Fino, E., et al.
(2015). Endocannabinoids mediate bidirectional striatal spike-timing-
dependent plasticity. J. Physiol. 593, 2833–2849. doi: 10.1113/JP
270324
Cummings, D. M., Andre, V. M., Uzgil, B. O., Gee, S. M., Fisher, Y. E., Cepeda, C.,
et al. (2009). Alterations in cortical excitation and inhibition in genetic mouse
models of Huntington’s disease. J. Neurosci. 29, 10371–10386. doi: 10.1523/
JNEUROSCI.1592-09.2009
Cummings, D. M., Cepeda, C., and Levine, M. S. (2010). Alterations in
striatal synaptic transmission are consistent across genetic mouse models of
Huntington’s disease. ASN Neuro 2:AN20100007. doi: 10.1042/AN20100007
Cummings, D. M., Milnerwood, A. J., Dallérac, G. M., Waights, V., Brown,
J. Y., Vatsavayai, S. C., et al. (2006). Aberrant cortical synaptic plasticity and
dopaminergic dysfunction in a mouse model of huntington’s disease. Hum. Mol.
Genet. 15, 2856–2868. doi: 10.1093/hmg/ddl224
Curtin, P. C. P., Farrar, A. M., Oakeshott, S., Sutphen, J., Berger, J., Mazzella, M.,
et al. (2015). Cognitive training at a young age attenuates deficits in the zQ175
mouse model of HD. Front. Behav. Neurosci. 9:361. doi: 10.3389/fnbeh.2015.
00361
Dallérac, G. M., Vatsavayai, S. C., Cummings, D. M., Milnerwood, A. J.,
Peddie, C. J., Evans, K. A., et al. (2011). Impaired long-term potentiation in
the prefrontal cortex of Huntington’s disease mouse models: rescue by D1
dopamine receptor activation. Neurodegener. Dis. 8, 230–239. doi: 10.1159/
000322540
Defelipe, J., López-Cruz, P. L., Benavides-Piccione, R., Bielza, C., Larrañaga,
P., Anderson, S., et al. (2013). New insights into the classification and
nomenclature of cortical GABAergic interneurons. Nat. Rev. Neurosci. 14,
202–216. doi: 10.1038/nrn3444
Deleuze, C., Bhumbra, G. S., Pazienti, A., Lourenço, J., Mailhes, C., Aguirre, A.,
et al. (2019). Strong preference for autaptic self-connectivity of neocortical PV
interneurons facilitates their tuning to γ-oscillations. PLoS Biol. 17:e3000419.
doi: 10.1371/journal.pbio.3000419
Deng, Y. P., Albin, R. L., Penney, J. B., Young, A. B., Anderson, K. D., and Reiner, A.
(2004). Differential loss of striatal projection systems in Huntington’s disease:
a quantitative immunohistochemical study. J. Chem. Neuroanat. 27, 143–164.
doi: 10.1016/j.jchemneu.2004.02.005
Deng, Y. P., Wong, T., Bricker-Anthony, C., Deng, B., and Reiner, A.
(2013). Loss of corticostriatal and thalamostriatal synaptic terminals
precedes striatal projection neuron pathology in heterozygous Q140
Huntington’s disease mice. Neurobiol. Dis. 60, 89–107. doi: 10.1016/j.nbd.2013.
08.009
Deng, Y.-P., Wong, T., Wan, J. Y., and Reiner, A. (2014). Differential loss of
thalamostriatal and corticostriatal input to striatal projection neuron types
prior to overt motor symptoms in the Q140 knock-in mouse model of
Huntington’s disease. Front. Syst. Neurosci. 8:198. doi: 10.3389/fnsys.2014.
00198
Denovan-Wright, E. M., and Robertson, H. A. (2000). Cannabinoid receptor
messenger RNA levels decrease in a subset of neurons of the lateral striatum,
cortex and hippocampus of transgenic Huntington’s disease mice. Neuroscience
98, 705–713. doi: 10.1016/S0306-4522(00)00157-153
Diaz-Castro, B., Gangwani, M. R., Yu, X., Coppola, G., and Khakh, B. S. (2019).
Astrocyte molecular signatures in Huntington’s disease. Sci. Transl. Med.
11:eaaw8546. doi: 10.1126/scitranslmed.aaw8546
DiFiglia, M. (1990). Excitotoxic injury of the neostriatum: a model for Huntington’s
disease. Trends Neurosci. 13, 286–289. doi: 10.1016/0166-2236(90)90111-m
Frontiers in Neuroscience | www.frontiersin.org 13 February 2020 | Volume 14 | Article 82
fnins-14-00082 February 4, 2020 Time: 17:14 # 14
Blumenstock and Dudanova Circuit Mechanisms of Huntington’s Disease
Donzis, E. J., Estrada-Sánchez, A. M., Indersmitten, T., Oikonomou, K., Tran,
C. H., Wang, C., et al. (2019). Cortical network dynamics is altered in mouse
models of Huntington’s disease. Cereb. Cortex bhz245. doi: 10.1093/cercor/
bhz245
Dougherty, S. E., Hollimon, J. J., McMeekin, L. J., Bohannon, A. S., West, A. B.,
Lesort, M., et al. (2014). Hyperactivity and cortical disinhibition in mice
with restricted expression of mutant huntingtin to parvalbumin-positive cells.
Neurobiol. Dis. 62, 160–171. doi: 10.1016/j.nbd.2013.10.002
Dowie, M. J., Bradshaw, H. B., Howard, M. L., Nicholson, L. F. B., Faull, R. L. M.,
Hannan, A. J., et al. (2009). Altered CB1 receptor and endocannabinoid levels
precede motor symptom onset in a transgenic mouse model of Huntington’s
disease. Neuroscience 163, 456–465. doi: 10.1016/j.neuroscience.2009.06.014
Dvorzhak, A., Vagner, T., Kirmse, K., and Grantyn, R. (2016). Functional indicators
of glutamate transport in single striatal astrocytes and the influence of Kir4.1 in
normal and Huntington Mice. J. Neurosci. Off. J. Soc. Neurosci. 36, 4959–4975.
doi: 10.1523/JNEUROSCI.0316-16.2016
Epping, E. A., and Paulsen, J. S. (2011). Depression in the early stages of
Huntington disease. Neurodegener. Dis. Manag. 1, 407–414. doi: 10.2217/nmt.
11.45
Estrada-Sánchez, A. M., and Rebec, G. V. (2012). Corticostriatal dysfunction and
glutamate transporter 1 (GLT1) in Huntington’s disease: interactions between
neurons and astrocytes. Basal Ganglia 2, 57–66. doi: 10.1016/j.baga.2012.04.029
Estrada-Sánchez, A. M., and Rebec, G. V. (2013). Role of cerebral cortex in the
neuropathology of Huntington’s disease. Front. Neural Circuits 7:19. doi: 10.
3389/fncir.2013.00019
Faideau, M., Kim, J., Cormier, K., Gilmore, R., Welch, M., Auregan, G., et al.
(2010). In vivo expression of polyglutamine-expanded huntingtin by mouse
striatal astrocytes impairs glutamate transport: a correlation with Huntington’s
disease subjects. Hum. Mol. Genet. 19, 3053–3067. doi: 10.1093/hmg/
ddq212
Ferrer, I., and Blanco, R. (2000). N-myc and c-myc expression in Alzheimer disease,
Huntington disease and Parkinson disease. Mol. Brain Res. 77, 270–276. doi:
10.1016/S0169-328X(00)00062-60
Galvan, L., André, V. M., Wang, E. A., Cepeda, C., and Levine, M. S. (2012).
Functional differences between direct and indirect striatal output pathways
in Huntington’s disease. J. Huntingt. Dis. 1, 17–25. doi: 10.3233/JHD-2012-
120009
Gardoni, F., and Bellone, C. (2015). Modulation of the glutamatergic transmission
by Dopamine: a focus on Parkinson, Huntington and Addiction diseases. Front.
Cell. Neurosci. 9:25. doi: 10.3389/fncel.2015.00025
Gerfen, C. R., and Surmeier, D. J. (2011). Modulation of striatal projection systems
by dopamine. Annu. Rev. Neurosci. 34, 441–466. doi: 10.1146/annurev-neuro-
061010-113641
Giampà, C., Middei, S., Patassini, S., Borreca, A., Marullo, F., Laurenti, D.,
et al. (2009). Phosphodiesterase type IV inhibition prevents sequestration
of CREB binding protein, protects striatal parvalbumin interneurons
and rescues motor deficits in the R6/2 mouse model of Huntington’s
disease. Eur. J. Neurosci. 29, 902–910. doi: 10.1111/j.1460-9568.2009.06
649.x
Giandomenico, S. L., Mierau, S. B., Gibbons, G. M., Wenger, L. M. D., Masullo,
L., Sit, T., et al. (2019). Cerebral organoids at the air-liquid interface generate
diverse nerve tracts with functional output. Nat. Neurosci. 22, 669–679. doi:
10.1038/s41593-019-0350-352
Ginés, S., Bosch, M., Marco, S., Gavaldà, N., Díaz-Hernández, M., Lucas, J. J., et al.
(2006). Reduced expression of the TrkB receptor in Huntington’s disease mouse
models and in human brain. Eur. J. Neurosci. 23, 649–658. doi: 10.1111/j.1460-
9568.2006.04590.x
Gittis, A. H., and Kreitzer, A. C. (2012). Striatal microcircuitry and movement
disorders. Trends Neurosci. 35, 557–564. doi: 10.1016/j.tins.2012.06.008
Glass, M., Dragunow, M., and Faull, R. L. M. (2000). The pattern of
neurodegeneration in Huntington’s disease: a comparative study of
cannabinoid, dopamine, adenosine and GABAA receptor alterations in
the human basal ganglia in Huntington’s disease. Neuroscience 97, 505–519.
doi: 10.1016/S0306-4522(00)00008-7
Gokce, O., Stanley, G. M., Treutlein, B., Neff, N. F., Camp, J. G., Malenka,
R. C., et al. (2016). Cellular Taxonomy of the Mouse Striatum as Revealed
by Single-Cell RNA-Seq. Cell Rep. 16, 1126–1137. doi: 10.1016/j.celrep.2016.
06.059
Grace, A. A. (2016). Dysregulation of the dopamine system in the pathophysiology
of schizophrenia and depression. Nat. Rev. Neurosci. 17, 524–532. doi: 10.1038/
nrn.2016.57
Gray, M., Shirasaki, D. I., Cepeda, C., André, V. M., Wilburn, B., Lu, X.-H.,
et al. (2008). Full-length human mutant huntingtin with a stable polyglutamine
repeat can elicit progressive and selective neuropathogenesis in BACHD mice.
J. Neurosci. Off. J. Soc. Neurosci. 28, 6182–6195. doi: 10.1523/JNEUROSCI.
0857-08.2008
Gremel, C. M., Chancey, J. H., Atwood, B. K., Luo, G., Neve, R., Ramakrishnan, C.,
et al. (2016). Endocannabinoid modulation of orbitostriatal circuits gates habit
formation. Neuron 90, 1312–1324. doi: 10.1016/j.neuron.2016.04.043
Gritton, H. J., Howe, W. M., Romano, M. F., DiFeliceantonio, A. G., Kramer,
M. A., Saligrama, V., et al. (2019). Unique contributions of parvalbumin and
cholinergic interneurons in organizing striatal networks during movement. Nat.
Neurosci. 22, 586–597. doi: 10.1038/s41593-019-0341-343
Groenewegen, H. J. (2003). The Basal Ganglia and motor control. Neural Plast. 10,
107–120. doi: 10.1155/NP.2003.107
Gu, X., Li, C., Wei, W., Lo, V., Gong, S., Li, S.-H., et al. (2005). Pathological Cell-
Cell interactions elicited by a neuropathogenic form of mutant Huntingtin
contribute to cortical pathogenesis in HD Mice. Neuron 46, 433–444. doi:
10.1016/j.neuron.2005.03.025
Guo, Z., Rudow, G., Pletnikova, O., Codispoti, K.-E., Orr, B. A., Crain, B. J.,
et al. (2012). Striatal neuronal loss correlates with clinical motor impairment
in Huntington’s disease. Mov. Disord. Off. J. Mov. Disord. Soc. 27, 1379–1386.
doi: 10.1002/mds.25159
Halliday, G. M., McRitchie, D. A., Macdonald, V., Double, K. L., Trent, R. J.,
and McCusker, E. (1998). Regional specificity of brain atrophy in Huntington’s
disease. Exp. Neurol. 154, 663–672. doi: 10.1006/exnr.1998.6919
HD iPSC Consortium (2017). Developmental alterations in Huntington’s disease
neural cells and pharmacological rescue in cells and mice. Nat. Neurosci. 20,
648–660. doi: 10.1038/nn.4532
Hedreen, J. C., and Folstein, S. E. (1995). Early loss of neostriatal striosome neurons
in Huntington’s disease. J. Neuropathol. Exp. Neurol. 54, 105–120. doi: 10.1097/
00005072-199501000-199501013
Hosp, F., Gutiérrez-Ángel, S., Schaefer, M. H., Cox, J., Meissner, F., Hipp, M. S.,
et al. (2017). Spatiotemporal proteomic profiling of Huntington’s disease
inclusions reveals widespread loss of protein function. Cell Rep. 21, 2291–2303.
doi: 10.1016/j.celrep.2017.10.097
Heikkinen, T., Lehtimäki, K., Vartiainen, N., Puoliväli, J., Hendricks, S. J., Glaser,
J. R., et al. (2012). Characterization of neurophysiological and behavioral
changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model
of Huntington’s disease. PLoS One 7:e0050717. doi: 10.1371/journal.pone.
0050717
Hilário, M. R. F., Clouse, E., Yin, H. H., and Costa, R. M. (2007). Endocannabinoid
signaling is critical for habit formation. Front. Integr. Neurosci. 1:6. doi: 10.3389/
neuro.07.006.2007
Hintiryan, H., Foster, N. N., Bowman, I., Bay, M., Song, M. Y., Gou, L., et al.
(2016). The mouse cortico-striatal projectome. Nat. Neurosci. 19, 1100–1114.
doi: 10.1038/nn.4332
Hodgson, J. G., Agopyan, N., Gutekunst, C. A., Leavitt, B. R., LePiane, F.,
Singaraja, R., et al. (1999). A YAC mouse model for Huntington’s disease
with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal
neurodegeneration. Neuron 23, 181–192. doi: 10.1016/s0896-6273(00)80764-
80763
Holley, S. M., Galvan, L., Kamdjou, T., Cepeda, C., and Levine, M. S. (2019a).
Striatal GABAergic interneuron dysfunction in the Q175 mouse model of
Huntington’s disease. Eur. J. Neurosci. 49, 79–93. doi: 10.1111/ejn.14283
Holley, S. M., Galvan, L., Kamdjou, T., Dong, A., Levine, M. S., and Cepeda,
C. (2019b). Major contribution of somatostatin-expressing interneurons and
cannabinoid receptors to increased GABA synaptic activity in the striatum of
Huntington’s disease mice. Front. Synaptic Neurosci. 11:14. doi: 10.3389/fnsyn.
2019.00014
Holley, S. M., Joshi, P. R., Parievsky, A., Galvan, L., Chen, J. Y., Fisher, Y. E.,
et al. (2015). Enhanced GABAergic inputs contribute to functional alterations
of cholinergic interneurons in the R6/2 mouse model of Huntington’s disease.
eNeuro 2:ENEURO.0008-14. doi: 10.1523/ENEURO.0008-14.2015
Hong, S. L., Cossyleon, D., Hussain, W. A., Walker, L. J., Barton, S. J., and
Rebec, G. V. (2012). Dysfunctional behavioral modulation of corticostriatal
Frontiers in Neuroscience | www.frontiersin.org 14 February 2020 | Volume 14 | Article 82
fnins-14-00082 February 4, 2020 Time: 17:14 # 15
Blumenstock and Dudanova Circuit Mechanisms of Huntington’s Disease
communication in the R6/2 mouse model of Huntington’s disease. PLoS One
7:e47026. doi: 10.1371/journal.pone.0047026
Hong, S. L., and Rebec, G. V. (2012). Biological sources of inflexibility in brain and
behavior with aging and neurodegenerative diseases. Front. Syst. Neurosci. 6:77.
doi: 10.3389/fnsys.2012.00077
Horne, E. A., Coy, J., Swinney, K., Fung, S., Cherry, A. E. T., Marrs, W. R.,
et al. (2013). Downregulation of cannabinoid receptor 1 from neuropeptide
Y interneurons in the basal ganglia of patients with Huntington’s disease and
mouse models. Eur. J. Neurosci. 37, 429–440. doi: 10.1111/ejn.12045
Hsu, Y.-T., Chang, Y.-G., and Chern, Y. (2018). Insights into GABAAergic system
alteration in Huntington’s disease. Open Biol. 8:180165. doi: 10.1098/rsob.
180165
Hu, H., Gan, J., and Jonas, P. (2014). Fast-spiking, parvalbumin+ GABAergic
interneurons: from cellular design to microcircuit function. Science
345:1255263. doi: 10.1126/science.1255263
Huang, Z. J. (2014). Toward a genetic dissection of cortical circuits in the
mouse. Neuron 83, 1284–1302. doi: 10.1016/j.neuron.2014.08.041 doi: 10.1016/
j.neuron.2014.08.041
Huang, C. C., Lo, S. W., and Hsu, K. S. (2001). Presynaptic mechanisms underlying
cannabinoid inhibition of excitatory synaptic transmission in rat striatal
neurons. J. Physiol. 532, 731–748. doi: 10.1111/j.1469-7793.2001.0731e.x
Indersmitten, T., Tran, C. H., Cepeda, C., and Levine, M. S. (2015). Altered
excitatory and inhibitory inputs to striatal medium-sized spiny neurons and
cortical pyramidal neurons in the Q175 mouse model of Huntington’s disease.
J. Neurophysiol. 113, 2953–2966. doi: 10.1152/jn.01056.2014
Jiang, R., Diaz-Castro, B., Looger, L. L., and Khakh, B. S. (2016). Dysfunctional
calcium and glutamate signaling in striatal astrocytes from Huntington’s disease
model mice. J. Neurosci. 36, 3453–3470. doi: 10.1523/JNEUROSCI.3693-15.
2016
Johnson, M. A., Rajan, V., Miller, C. E., and Wightman, R. M. (2006). Dopamine
release is severely compromised in the R6/2 mouse model of Huntington’s
disease. J. Neurochem. 97, 737–746. doi: 10.1111/j.1471-4159.2006.
03762.x
Joshi, P. R., Wu, N.-P., Andre, V. M., Cummings, D. M., Cepeda, C., Joyce, J. A.,
et al. (2009). Age-Dependent alterations of corticostriatal activity in the YAC128
mouse model of Huntington disease. J. Neurosci. 29, 2414–2427. doi: 10.1523/
JNEUROSCI.5687-08.2009
Khakh, B. S., Beaumont, V., Cachope, R., Munoz-Sanjuan, I., Goldman, S. A.,
and Grantyn, R. (2017). Unravelling and exploiting astrocyte dysfunction in
Huntington’s disease. Trends Neurosci. 40, 422–437. doi: 10.1016/j.tins.2017.05.
002
Kim, E. H., Thu, D. C. V., Tippett, L. J., Oorschot, D. E., Hogg, V. M., Roxburgh,
R., et al. (2014). Cortical interneuron loss and symptom heterogeneity in
Huntington disease: interneuron Loss in HD cortex. Ann. Neurol. 75, 717–727.
doi: 10.1002/ana.24162
Kiyatkin, E. A., and Rebec, G. V. (1999). Striatal neuronal activity and
responsiveness to dopamine and glutamate after selective blockade of D1 and
D2 dopamine receptors in freely moving rats. J. Neurosci. 19, 3594–3609. doi:
10.1523/JNEUROSCI.19-09-03594.1999
Klapstein, G. J., Fisher, R. S., Zanjani, H., Cepeda, C., Jokel, E. S., Chesselet, M.-
F., et al. (2001). Electrophysiological and morphological changes in striatal
spiny neurons in R6/2 Huntington’s disease transgenic mice. J. Neurophysiol.
86, 2667–2677. doi: 10.1152/jn.2001.86.6.2667
Klaus, A., Martins, G. J., Paixao, V. B., Zhou, P., Paninski, L., and Costa, R. M.
(2017). The spatiotemporal organization of the striatum encodes action space.
Neuron 95:1171-1180.e7. doi: 10.1016/j.neuron.2017.08.015
Koch, E. T., and Raymond, L. A. (2019). Dysfunctional striatal dopamine signaling
in Huntington’s disease. J. Neurosci. Res. 97, 1636–1654. doi: 10.1002/jnr.24495
Kolodziejczyk, K., and Raymond, L. A. (2016). Differential changes in thalamic
and cortical excitatory synapses onto striatal spiny projection neurons in a
Huntington disease mouse model. Neurobiol. Dis. 86, 62–74. doi: 10.1016/j.nbd.
2015.11.020
Laforet, G. A., Sapp, E., Chase, K., McIntyre, C., Boyce, F. M., Campbell, M.,
et al. (2001). Changes in cortical and striatal neurons predict behavioral
and electrophysiological abnormalities in a transgenic murine model of
Huntington’s disease. J. Neurosci. 21, 9112–9123. doi: 10.1523/JNEUROSCI.21-
23-09112.2001
Lancaster, M. A., Renner, M., Martin, C.-A., Wenzel, D., Bicknell, L. S., Hurles,
M. E., et al. (2013). Cerebral organoids model human brain development and
microcephaly. Nature 501, 373–379. doi: 10.1038/nature12517
Lange, H., Thörner, G., Hopf, A., and Schröder, K. F. (1976). Morphometric
studies of the neuropathological changes in choreatic diseases. J. Neurol. Sci.
28, 401–425. doi: 10.1016/0022-510x(76)90114-90113
Langfelder, P., Cantle, J. P., Chatzopoulou, D., Wang, N., Gao, F., Al-Ramahi,
I., et al. (2016). Integrated genomics and proteomics define huntingtin CAG
length–dependent networks in mice. Nat. Neurosci. 19, 623–633. doi: 10.1038/
nn.4256
Lawrence, A. D., Sahakian, B. J., Hodges, J. R., Rosser, A. E., Lange, K. W.,
and Robbins, T. W. (1996). Executive and mnemonic functions in early
Huntington’s disease. Brain J. Neurol. 119(Pt 5), 1633–1645. doi: 10.1093/brain/
119.5.1633
Lee, K., Holley, S. M., Shobe, J. L., Chong, N. C., Cepeda, C., Levine, M. S.,
et al. (2017). Parvalbumin interneurons modulate striatal output and enhance
performance during associative learning. Neuron 93:1451-1463.e4. doi: 10.
1016/j.neuron.2017.02.033
Liévens, J. C., Woodman, B., Mahal, A., Spasic-Boscovic, O., Samuel, D., Kerkerian-
Le Goff, L., et al. (2001). Impaired glutamate uptake in the R6 Huntington’s
disease transgenic mice. Neurobiol. Dis. 8, 807–821. doi: 10.1006/nbdi.2001.
0430
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington,
C., et al. (1996). Exon 1 of the HD Gene with an expanded CAG repeat is
sufficient to cause a progressive neurological phenotype in transgenic mice. Cell
87, 493–506. doi: 10.1016/S0092-8674(00)81369-81360
Martinez-Horta, S., Perez-Perez, J., van Duijn, E., Fernandez-Bobadilla, R.,
Carceller, M., Pagonabarraga, J., et al. (2016). Neuropsychiatric symptoms
are very common in premanifest and early stage Huntington’s disease.
Parkinsonism Relat. Disord. 25, 58–64. doi: 10.1016/j.parkreldis.2016.
02.008
Mateo, Y., Johnson, K. A., Covey, D. P., Atwood, B. K., Wang, H.-L., Zhang,
S., et al. (2017). Endocannabinoid actions on cortical terminals orchestrate
local modulation of dopamine release in the nucleus accumbens. Neuron 96:
1112-1126.e5. doi: 10.1016/j.neuron.2017.11.012
Mehrabi, N. F., Waldvogel, H. J., Tippett, L. J., Hogg, V. M., Synek, B. J., and Faull,
R. L. M. (2016). Symptom heterogeneity in Huntington’s disease correlates
with neuronal degeneration in the cerebral cortex. Neurobiol. Dis. 96, 67–74.
doi: 10.1016/j.nbd.2016.08.015
Menalled, L. B., Kudwa, A. E., Miller, S., Fitzpatrick, J., Watson-Johnson,
J., Keating, N., et al. (2012). Comprehensive behavioral and molecular
characterization of a new knock-in mouse model of Huntington’s disease:
zQ175. PLoS One 7:e49838. doi: 10.1371/journal.pone.0049838
Menalled, L. B., Sison, J. D., Dragatsis, I., Zeitlin, S., and Chesselet, M.-F. (2003).
Time course of early motor and neuropathological anomalies in a knock-in
mouse model of Huntington’s disease with 140 CAG repeats. J. Comp. Neurol.
465, 11–26. doi: 10.1002/cne.10776
Menalled, L. B., Sison, J. D., Wu, Y., Olivieri, M., Li, X.-J., Li, H., et al. (2002). Early
motor dysfunction and striosomal distribution of huntingtin microaggregates
in Huntington’s disease knock-in mice. J. Neurosci. Off. J. Soc. Neurosci. 22,
8266–8276. doi: 10.1523/jneurosci.22-18-08266.2002
Meunier, C., Merienne, N., Jollé, C., Déglon, N., and Pellerin, L. (2016). Astrocytes
are key but indirect contributors to the development of the symptomatology
and pathophysiology of Huntington’s disease: astrocytes in Huntington’s
disease. Glia 64, 1841–1856. doi: 10.1002/glia.23022
Mievis, S., Blum, D., and Ledent, C. (2011). Worsening of Huntington disease
phenotype in CB1 receptor knockout mice. Neurobiol. Dis. 42, 524–529. doi:
10.1016/j.nbd.2011.03.006
Miller, B. R., and Bezprozvanny, I. (2010). Corticostriatal circuit dysfunction in
Huntington’s disease: intersection of glutamate, dopamine and calcium. Future
Neurol. 5, 735–756. doi: 10.2217/fnl.10.41
Miller, B. R., Dorner, J. L., Shou, M., Sari, Y., Barton, S. J., Sengelaub, D. R., et al.
(2008a). Up-regulation of GLT1 expression increases glutamate uptake and
attenuates the Huntington’s disease phenotype in the R6/2 mouse. Neuroscience
153, 329–337. doi: 10.1016/j.neuroscience.2008.02.004
Miller, B. R., Walker, A. G., Barton, S. J., and Rebec, G. V. (2011). Dysregulated
neuronal activity patterns implicate corticostriatal circuit dysfunction in
Frontiers in Neuroscience | www.frontiersin.org 15 February 2020 | Volume 14 | Article 82
fnins-14-00082 February 4, 2020 Time: 17:14 # 16
Blumenstock and Dudanova Circuit Mechanisms of Huntington’s Disease
multiple rodent models of Huntington’s disease. Front. Syst. Neurosci. 5:26.
doi: 10.3389/fnsys.2011.00026
Miller, B. R., Walker, A. G., Fowler, S. C., von Hörsten, S., Riess, O., Johnson, M. A.,
et al. (2010). Dysregulation of coordinated neuronal firing patterns in striatum
of freely behaving transgenic rats that model Huntington’s disease. Neurobiol.
Dis. 37, 106–113. doi: 10.1016/j.nbd.2009.09.013
Miller, B. R., Walker, A. G., Shah, A. S., Barton, S. J., and Rebec, G. V. (2008b).
Dysregulated information processing by medium spiny neurons in striatum of
freely behaving mouse models of Huntington’s disease. J. Neurophysiol. 100,
2205–2216. doi: 10.1152/jn.90606.2008
Milnerwood, A. J., Gladding, C. M., Pouladi, M. A., Kaufman, A. M., Hines,
R. M., Boyd, J. D., et al. (2010). Early increase in extrasynaptic NMDA receptor
signaling and expression contributes to phenotype onset in Huntington’s
disease mice. Neuron 65, 178–190. doi: 10.1016/j.neuron.2010.01.008
Murmu, R. P., Li, W., Holtmaat, A., and Li, J.-Y. (2013). Dendritic Spine instability
leads to progressive neocortical spine loss in a mouse model of Huntington’s
disease. J. Neurosci. 33, 12997–13009. doi: 10.1523/JNEUROSCI.5284-12.2013
Murmu, R. P., Li, W., Szepesi, Z., and Li, J.-Y. (2015). Altered sensory experience
exacerbates stable Dendritic Spine and synapse loss in a mouse model of
Huntington’s disease. J. Neurosci. 35, 287–298. doi: 10.1523/JNEUROSCI.0244-
14.2015
Nambu, A., Tokuno, H., and Takada, M. (2002). Functional significance of the
cortico-subthalamo-pallidal “hyperdirect” pathway. Neurosci. Res. 43, 111–117.
doi: 10.1016/s0168-0102(02)00027-25
Nardone, R., Lochner, P., Marth, R., Ausserer, H., Bratti, A., and Tezzon, F. (2007).
Abnormal intracortical facilitation in early-stage Huntington’s disease. Clin.
Neurophysiol. 118, 1149–1154. doi: 10.1016/j.clinph.2007.01.009
Naydenov, A. V., Sepers, M. D., Swinney, K., Raymond, L. A., Palmiter, R. D., and
Stella, N. (2014). Genetic rescue of CB1 receptors on medium spiny neurons
prevents loss of excitatory striatal synapses but not motor impairment in HD
mice. Neurobiol. Dis. 71, 140–150. doi: 10.1016/j.nbd.2014.08.009
Naze, S., Humble, J., Zheng, P., Barton, S., Rangel-Barajas, C., Rebec, G. V.,
et al. (2018). Cortico-striatal cross-frequency coupling and gamma genesis
disruptions in Huntington’s disease mouse and computational models. eNeuro
5:ENEURO.210-18. doi: 10.1523/ENEURO.0210-18.2018
Nopoulos, P. C., Aylward, E. H., Ross, C. A., Johnson, H. J., Magnotta, V. A., Juhl,
A. R., et al. (2010). Cerebral cortex structure in prodromal Huntington disease.
Neurobiol. Dis. 40, 544–554. doi: 10.1016/j.nbd.2010.07.014
Okamoto, S., Pouladi, M. A., Talantova, M., Yao, D., Xia, P., Ehrnhoefer, D. E.,
et al. (2009). Balance between synaptic versus extrasynaptic NMDA receptor
activity influences inclusions and neurotoxicity of mutant huntingtin. Nat. Med.
15, 1407–1413. doi: 10.1038/nm.2056
Oyanagi, K., Takeda, S., Takahashi, H., Ohama, E., and Ikuta, F. (1989). A
quantitative investigation of the substantia nigra in Huntington’s disease. Ann.
Neurol. 26, 13–19. doi: 10.1002/ana.410260103
Parievsky, A., Moore, C., Kamdjou, T., Cepeda, C., Meshul, C. K., and Levine,
M. S. (2017). Differential electrophysiological and morphological alterations
of thalamostriatal and corticostriatal projections in the R6/2 mouse model of
Huntington’s disease. Neurobiol. Dis. 108, 29–44. doi: 10.1016/j.nbd.2017.07.
020
Parker, J. G., Marshall, J. D., Ahanonu, B., Wu, Y.-W., Kim, T. H., Grewe, B. F., et al.
(2018). Diametric neural ensemble dynamics in parkinsonian and dyskinetic
states. Nature 557, 177–182. doi: 10.1038/s41586-018-0090-96
Parsons, M. P., Vanni, M. P., Woodard, C. L., Kang, R., Murphy, T. H., and
Raymond, L. A. (2016). Real-time imaging of glutamate clearance reveals
normal striatal uptake in Huntington disease mouse models. Nat. Commun.
7:11251. doi: 10.1038/ncomms11251
Peters, A. J., Steinmetz, N. A., Harris, K. D., and Carandini, M. (2019). Striatal
activity reflects cortical activity patterns. bioRxiv [Preprint] doi: 10.1101/
703710
Petersén, Å, Puschban, Z., Lotharius, J., NicNiocaill, B., Wiekop, P., O’Connor,
W. T., et al. (2002). Evidence for dysfunction of the nigrostriatal pathway in the
R6/1 line of transgenic Huntington’s disease mice. Neurobiol. Dis. 11, 134–146.
doi: 10.1006/nbdi.2002.0534
Pfeffer, C. K., Xue, M., He, M., Huang, Z. J., and Scanziani, M. (2013). Inhibition of
inhibition in visual cortex: the logic of connections between molecularly distinct
interneurons. Nat. Neurosci. 16, 1068–1076. doi: 10.1038/nn.3446
Philpott, A. L., Cummins, T. D. R., Bailey, N. W., Churchyard, A., Fitzgerald, P. B.,
and Georgiou-Karistianis, N. (2016). Cortical inhibitory deficits in premanifest
and early Huntington’s disease. Behav. Brain Res. 296, 311–317. doi: 10.1016/j.
bbr.2015.09.030
Plotkin, J. L., and Goldberg, J. A. (2018). Thinking outside the box (and Arrow):
current themes in Striatal dysfunction in movement disorders. Neuroscientist
25, 359–379. doi: 10.1177/1073858418807887
Plotkin, J. L., and Surmeier, D. J. (2015). Corticostriatal synaptic adaptations in
Huntington’s disease. Curr. Opin. Neurobiol. 33, 53–62. doi: 10.1016/j.conb.
2015.01.020
Pouladi, M. A., Morton, A. J., and Hayden, M. R. (2013). Choosing an animal
model for the study of Huntington’s disease. Nat. Rev. Neurosci. 14, 708–721.
doi: 10.1038/nrn3570
Pouladi, M. A., Stanek, L. M., Xie, Y., Franciosi, S., Southwell, A. L., Deng, Y.,
et al. (2012). Marked differences in neurochemistry and aggregates despite
similar behavioural and neuropathological features of Huntington disease in
the full-length BACHD and YAC128 mice. Hum. Mol. Genet. 21, 2219–2232.
doi: 10.1093/hmg/dds037
Rangel-Barajas, C., and Rebec, G. V. (2016). Dysregulation of corticostriatal
connectivity in Huntington’s disease: a role for dopamine modulation.
J. Huntingt. Dis. 5, 303–331. doi: 10.3233/JHD-160221
Ransom, B. R., and Ransom, C. B. (2012). Astrocytes: multitalented stars of the
central nervous system. Methods Mol. Biol. Clifton NJ 814, 3–7. doi: 10.1007/
978-1-61779-452-0_1
Raymond, L. A., André, V. M., Cepeda, C., Gladding, C. M., Milnerwood, A. J., and
Levine, M. S. (2011). Pathophysiology of Huntington’s disease: time-dependent
alterations in synaptic and receptor function. Neuroscience 198, 252–273. doi:
10.1016/j.neuroscience.2011.08.052
Reading, S. A. J., Dziorny, A. C., Peroutka, L. A., Schreiber, M., Gourley, L. M.,
Yallapragada, V., et al. (2004). Functional brain changes in presymptomatic
Huntington’s disease. Ann. Neurol. 55, 879–883. doi: 10.1002/ana.20121
Rebec, G. V. (2018). Corticostriatal network dysfunction in Huntington’s disease:
deficits in neural processing, glutamate transport, and ascorbate release. CNS
Neurosci. Ther. 24, 281–291. doi: 10.1111/cns.12828
Rebec, G. V., Conroy, S. K., and Barton, S. J. (2006). Hyperactive striatal
neurons in symptomatic Huntington R6/2 mice: variations with behavioral state
and repeated ascorbate treatment. Neuroscience 137, 327–336. doi: 10.1016/j.
neuroscience.2005.08.062
Reiner, A., Albin, R. L., Anderson, K. D., D’Amato, C. J., Penney, J. B., and Young,
A. B. (1988). Differential loss of striatal projection neurons in Huntington
disease. Proc. Natl. Acad. Sci. U.S.A. 85, 5733–5737. doi: 10.1073/pnas.85.15.
5733
Reiner, A., and Deng, Y.-P. (2018). Disrupted striatal neuron inputs and outputs in
Huntington’s disease. CNS Neurosci. Ther. 24, 250–280. doi: 10.1111/cns.12844
Reiner, A., Shelby, E., Wang, H., Demarch, Z., Deng, Y., Guley, N. H., et al.
(2013). Striatal parvalbuminergic neurons are lost in Huntington’s disease:
implications for dystonia. Mov. Disord. Off. J. Mov. Disord. Soc. 28, 1691–1699.
doi: 10.1002/mds.25624
Renoir, T., Argyropoulos, A., and Hannan, A. J. (2012). Antidepressant-Like effect
of the norepinephrine-dopamine reuptake inhibitor bupropion in a mouse
model of Huntington’s disease with dopaminergic dysfunction. J. Huntingt. Dis.
1, 261–266. doi: 10.3233/JHD-120039
Richfield, E. K., O’Brien, C. F., Eskin, T., and Shoulson, I. (1991). Heterogeneous
dopamine receptor changes in early and late Huntington’s disease. Neurosci.
Lett. 132, 121–126. doi: 10.1016/0304-3940(91)90448-90443
Roos, R. A. (2010). Huntington’s disease: a clinical review. Orphanet J Rare Dis
5:40.
Rosas, H. D., Hevelone, N. D., Zaleta, A. K., Greve, D. N., Salat, D. H., and Fischl,
B. (2005). Regional cortical thinning in preclinical Huntington disease and its
relationship to cognition. Neurology 65:745. doi: 10.1212/01.wnl.0000174432.
87383.87
Rosas, H. D., Salat, D. H., Lee, S. Y., Zaleta, A. K., Pappu, V., Fischl, B., et al. (2008).
Cerebral cortex and the clinical expression of Huntington’s disease: complexity
and heterogeneity. Brain 131, 1057–1068. doi: 10.1093/brain/awn025
Ross, C. A., Aylward, E. H., Wild, E. J., Langbehn, D. R., Long, J. D., Warner, J. H.,
et al. (2014). Huntington disease: natural history, biomarkers and prospects for
therapeutics. Nat. Rev. Neurol. 10, 204–216. doi: 10.1038/nrneurol.2014.24
Frontiers in Neuroscience | www.frontiersin.org 16 February 2020 | Volume 14 | Article 82
fnins-14-00082 February 4, 2020 Time: 17:14 # 17
Blumenstock and Dudanova Circuit Mechanisms of Huntington’s Disease
Rothe, T., Deliano, M., Wójtowicz, A. M., Dvorzhak, A., Harnack, D., Paul, S., et al.
(2015). Pathological gamma oscillations, impaired dopamine release, synapse
loss and reduced dynamic range of unitary glutamatergic synaptic transmission
in the striatum of hypokinetic Q175 Huntington mice. Neuroscience 311,
519–538. doi: 10.1016/j.neuroscience.2015.10.039
Ruiz-Calvo, A., Maroto, I. B., Bajo-Grañeras, R., Chiarlone, A., Gaudioso,
Á, Ferrero, J. J., et al. (2018). Pathway-specific control of striatal neuron
vulnerability by corticostriatal cannabinoid CB1 receptors. Cereb. Cortex 28,
307–322. doi: 10.1093/cercor/bhx285
Schippling, S., Schneider, S. A., Bhatia, K. P., Münchau, A., Rothwell, J. C., Tabrizi,
S. J., et al. (2009). Abnormal motor cortex excitability in preclinical and very
early Huntington’s disease. Biol. Psychiatry 65, 959–965. doi: 10.1016/j.biopsych.
2008.12.026
Sepers, M. D., Smith-Dijak, A., LeDue, J., Kolodziejczyk, K., Mackie, K., and
Raymond, L. A. (2018). Endocannabinoid-specific impairment in synaptic
plasticity in striatum of Huntington’s disease mouse model. J. Neurosci. 38,
544–554. doi: 10.1523/JNEUROSCI.1739-17.2017
Shin, J.-Y., Fang, Z.-H., Yu, Z.-X., Wang, C.-E., Li, S.-H., and Li, X.-J. (2005).
Expression of mutant huntingtin in glial cells contributes to neuronal
excitotoxicity. J. Cell Biol. 171, 1001–1012. doi: 10.1083/jcb.200508072
Shirasaki, D. I., Greiner, E. R., Al-Ramahi, I., Gray, M., Boontheung, P., Geschwind,
D. H., et al. (2012). Network organization of the huntingtin proteomic
interactome in mammalian brain. Neuron 75, 41–57. doi: 10.1016/j.neuron.
2012.05.024
Skotte, N. H., Andersen, J. V., Santos, A., Aldana, B. I., Willert, C. W., Nørremølle,
A., et al. (2018). Integrative characterization of the R6/2 mouse model of
Huntington’s disease reveals dysfunctional astrocyte metabolism. Cell Rep. 23,
2211–2224. doi: 10.1016/j.celrep.2018.04.052
Sleezer, B. J., and Hayden, B. Y. (2016). Differential contributions of Ventral and
Dorsal Striatum to early and late phases of cognitive set reconfiguration. J. Cogn.
Neurosci. 28, 1849–1864. doi: 10.1162/jocn_a_01011
Slow, E. J., van Raamsdonk, J., Rogers, D., Coleman, S. H., Graham, R. K., Deng,
Y., et al. (2003). Selective striatal neuronal loss in a YAC128 mouse model
of Huntington disease. Hum. Mol. Genet. 12, 1555–1567. doi: 10.1093/hmg/
ddg169
Smith-Dijak, A. I, Sepers, M. D., and Raymond, L. A. (2019). Alterations in synaptic
function and plasticity in Huntington disease. J. Neurochem. 150, 346–365.
doi: 10.1111/jnc.14723
Spampanato, J., Gu, X., Yang, X. W., and Mody, I. (2008). Progressive synaptic
pathology of motor cortical neurons in a BAC transgenic mouse model of
Huntington’s disease. Neuroscience 157, 606–620. doi: 10.1016/j.neuroscience.
2008.09.020
Spires, T. L. (2004). Environmental enrichment rescues protein deficits in a
mouse model of Huntington’s disease, indicating a possible disease mechanism.
J. Neurosci. 24, 2270–2276. doi: 10.1523/JNEUROSCI.1658-03.2004
Spokes, E. G. S. (1980). Neurochemical alterations in Huntington’s chorea: a
study of post-mortem brain tissue. Brain 103, 179–210. doi: 10.1093/brain/103.
1.179
Stern, E. A. (2011). Functional changes in neocortical activity in Huntington’s
disease model mice: an in vivo intracellular study. Front. Syst. Neurosci. 5:47.
doi: 10.3389/fnsys.2011.00047
Strand, A. D., Baquet, Z. C., Aragaki, A. K., Holmans, P., Yang, L., Cleren, C.,
et al. (2007). Expression profiling of Huntington’s disease models suggests
that brain-derived neurotrophic factor depletion plays a major role in striatal
degeneration. J. Neurosci. 27, 11758–11768. doi: 10.1523/JNEUROSCI.2461-07.
2007
Straub, C., Saulnier, J. L., Bègue, A., Feng, D. D., Huang, K. W., and Sabatini, B. L.
(2016). Principles of synaptic organization of GABAergic interneurons in the
striatum. Neuron 92, 84–92. doi: 10.1016/j.neuron.2016.09.007
Suzuki, M., Desmond, T. J., Albin, R. L., and Frey, K. A. (2001). Vesicular
neurotransmitter transporters in Huntington’s disease: Initial observations and
comparison with traditional synaptic markers. Synapse 41, 329–336. doi: 10.
1002/syn.1089
Tabrizi, S. J., Scahill, R. I., Owen, G., Durr, A., Leavitt, B. R., Roos, R. A., et al.
(2013). Predictors of phenotypic progression and disease onset in premanifest
and early-stage Huntington’s disease in the TRACK-HD study: analysis of 36-
month observational data. Lancet Neurol. 12, 637–649. doi: 10.1016/S1474-
4422(13)70088-70087
Tanimura, A., Lim, S. A. O., de .Aceves Buendia, J. J., Goldberg, J. A., and Surmeier,
D. J. (2016). Cholinergic interneurons amplify corticostriatal synaptic responses
in the Q175 model of Huntington’s disease. Front. Syst. Neurosci. 10:102. doi:
10.3389/fnsys.2016.00102
Tasic, B., Menon, V., Nguyen, T. N., Kim, T. K., Jarsky, T., Yao, Z., et al. (2016).
Adult mouse cortical cell taxonomy revealed by single cell transcriptomics. Nat.
Neurosci. 19, 335–346. doi: 10.1038/nn.4216
Tasic, B., Yao, Z., Graybuck, L. T., Smith, K. A., Nguyen, T. N., Bertagnolli,
D., et al. (2018). Shared and distinct transcriptomic cell types across
neocortical areas. Nature 563, 72–78. doi: 10.1038/s41586-018-065
4-655
The Huntington’s Disease collaborative research group (1993). A novel gene
containing a trinucleotide repeat that is expanded and unstable on Huntington’s
disease chromosomes. Cell 72, 971–983. doi: 10.1016/0092-8674(93)
90585-E
Thu, D. C. V., Oorschot, D. E., Tippett, L. J., Nana, A. L., Hogg, V. M., Synek,
B. J., et al. (2010). Cell loss in the motor and cingulate cortex correlates with
symptomatology in Huntington’s disease. Brain 133, 1094–1110. doi: 10.1093/
brain/awq047
Tong, X., Ao, Y., Faas, G. C., Nwaobi, S. E., Xu, J., Haustein, M. D., et al. (2014).
Astrocyte Kir4.1 ion channel deficits contribute to neuronal dysfunction in
Huntington’s disease model mice. Nat. Neurosci. 17, 694–703. doi: 10.1038/nn.
3691
Tremblay, R., Lee, S., and Rudy, B. (2016). GABAergic interneurons in the
neocortex: from cellular properties to circuits. Neuron 91, 260–292. doi: 10.
1016/j.neuron.2016.06.033
Tritsch, N. X., and Sabatini, B. L. (2012). Dopaminergic Modulation of Synaptic
Transmission in Cortex and Striatum. Neuron 76, 33–50. doi: 10.1016/j.neuron.
2012.09.023
Tsutsui-Kimura, I., Takiue, H., Yoshida, K., Xu, M., Yano, R., Ohta, H., et al. (2017).
Dysfunction of ventrolateral striatal dopamine receptor type 2-expressing
medium spiny neurons impairs instrumental motivation. Nat. Commun.
8:14304. doi: 10.1038/ncomms14304
Unschuld, P. G., Joel, S. E., Liu, X., Shanahan, M., Margolis, R. L., Biglan, K. M.,
et al. (2012). Impaired cortico-striatal functional connectivity in prodromal
Huntington’s Disease. Neurosci. Lett. 514, 204–209. doi: 10.1016/j.neulet.2012.
02.095
Van Laere, K., Casteels, C., Dhollander, I., Goffin, K., Grachev, I., Bormans, G.,
et al. (2010). Widespread decrease of type 1 cannabinoid receptor availability
in Huntington disease in vivo. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 51,
1413–1417. doi: 10.2967/jnumed.110.077156
Veit, J., Hakim, R., Jadi, M. P., Sejnowski, T. J., and Adesnik, H. (2017).
Cortical gamma band synchronization through somatostatin interneurons. Nat.
Neurosci. 20, 951–959. doi: 10.1038/nn.4562
Veldman, M. B., and Yang, X. W. (2018). Molecular insights into cortico-striatal
miscommunications in Huntington’s disease. Curr. Opin. Neurobiol. 48, 79–89.
doi: 10.1016/j.conb.2017.10.019
Victor, M. B., Richner, M., Olsen, H. E., Lee, S. W., Monteys, A. M., Ma, C., et al.
(2018). Striatal neurons directly converted from Huntington’s disease patient
fibroblasts recapitulate age-associated disease phenotypes. Nat. Neurosci. 21,
341–352. doi: 10.1038/s41593-018-0075-77
Virlogeux, A., Moutaux, E., Christaller, W., Genoux, A., Bruyère, J., Fino, E.,
et al. (2018). Reconstituting corticostriatal network on-a-chip reveals the
contribution of the presynaptic compartment to Huntington’s disease. Cell Rep.
22, 110–122. doi: 10.1016/j.celrep.2017.12.013
Waldvogel, H. J., Kim, E. H., Tippett, L. J., Vonsattel, J.-P. G., and Faull,
R. L. (2015). “The neuropathology of huntington’s disease,” in Behavioral
Neurobiology of Huntington’s Disease and Parkinson’s Disease Current Topics
in Behavioral Neurosciences, eds H. H. P. Nguyen, and M. A. Cenci, (Berlin:
Springer Berlin Heidelberg), 33–80. doi: 10.1007/7854_2014_354
Walker, A. G., Miller, B. R., Fritsch, J. N., Barton, S. J., and Rebec, G. V. (2008).
Altered information processing in the prefrontal cortex of Huntington’s disease
mouse models. J. Neurosci. 28, 8973–8982. doi: 10.1523/JNEUROSCI.2804-08.
2008
Walker, A. G., Ummel, J. R., and Rebec, G. V. (2011). Reduced expression of
conditioned fear in the R6/2 mouse model of Huntington’s disease is related
to abnormal activity in prelimbic cortex. Neurobiol. Dis. 43, 379–387. doi:
10.1016/j.nbd.2011.04.009
Frontiers in Neuroscience | www.frontiersin.org 17 February 2020 | Volume 14 | Article 82
fnins-14-00082 February 4, 2020 Time: 17:14 # 18
Blumenstock and Dudanova Circuit Mechanisms of Huntington’s Disease
Wang, Y., Toledo-Rodriguez, M., Gupta, A., Wu, C., Silberberg, G., Luo, J.,
et al. (2004). Anatomical, physiological and molecular properties of martinotti
cells in the somatosensory cortex of the juvenile rat: martinotti cells in
somatosensory cortex. J. Physiol. 561, 65–90. doi: 10.1113/jphysiol.2004.073353
Weeks, R. A., Piccini, P., Harding, A. E., and Brooks, D. J. (1996). Striatal D1 and
D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington’s
disease. Ann. Neurol. 40, 49–54. doi: 10.1002/ana.410400110
Werner, C. T., Williams, C. J., Fermelia, M. R., Lin, D.-T., and Li, Y. (2019). Circuit
mechanisms of neurodegenerative diseases: a new frontier with miniature
fluorescence microscopy. Front. Neurosci. 13:1174. doi: 10.3389/fnins.2019.
01174
Yu, C., Li, C. H., Chen, S., Yoo, H., Qin, X., and Park, H. (2018). Decreased BDNF
release in cortical neurons of a knock-in mouse model of Huntington’s disease.
Sci. Rep. 8:16976. doi: 10.1038/s41598-018-34883-w
Zeisel, A., Muñoz-Manchado, A. B., Codeluppi, S., Lönnerberg, P., La Manno,
G., Juréus, A., et al. (2015). Brain structure. Cell types in the mouse cortex
and hippocampus revealed by single-cell RNA-seq. Science 347, 1138–1142.
doi: 10.1126/science.aaa1934
Zuccato, C. (2001). Loss of huntingtin-mediated BDNF Gene Transcription
in Huntington’s disease. Science 293, 493–498. doi: 10.1126/science.105
9581
Zuccato, C., Liber, D., Ramos, C., Tarditi, A., Rigamonti, D., Tartari, M., et al.
(2005). Progressive loss of BDNF in a mouse model of Huntington’s disease
and rescue by BDNF delivery. Pharmacol. Res. 52, 133–139. doi: 10.1016/j.phrs.
2005.01.001
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Blumenstock and Dudanova. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice. No
use, distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Neuroscience | www.frontiersin.org 18 February 2020 | Volume 14 | Article 82
